" Thunder God Vine " vs Cancer ( &c ) ( Lei Gong Teng //
Tripterygium Wilfordii Hook )

**![](0logo.gif)  
  
[rexresearch.com](../index.htm)**  


---

**" Thunder God Vine " vs Cancer (
&c )**  
**( Lei Gong Teng // Tripterygium Wilfordii Hook )**

---

**Crug Farms  ( UK )**

![](crug.jpg)  
 **Tripterygium Wilfordii Hook**

---

 **[Press Reports](#press)  
  
[Journal Articles](#journals)  
  
[Patents -- Cultivation & Extraction, vs
Cancer &c](#patents)  
  
[Botany & Cultivation](#cultiv)**


---

[**http://naturalsociety.com/chinese-plant-compound-cancer-research/**](http://naturalsociety.com/chinese-plant-compound-cancer-research/)**October 18th, 2012**

**Chinese Plant Compound Wipes out
Cancer in 40 Days, Says New Research**  
  
**by**   
  
**Anthony Gucciardi**

A little-known plant with a truly bizarre name is now making
headlines as a cancer killer, with the compound of the plant
vanishing tumors in mice with pancreatic cancer. Known as the
thunder god vine or lei gong teng, the Chinese plant is actually
integrated into Chinese medicine and has been used for ages in
remedying a number of conditions including rheumatoid arthritis.  
  
According to the new research out of the University of Minnesotas
Masonic Cancer Center, the thunder god plant compound led to no
signs of tumors after a 40 day period  even after discontinuing
the treatment. Published in the journal Science Translational
Medicine and funded by the National Institutes of Health, even the
scientists working on the project were stunned by the anti-cancer
properties of the compound. Known to contain something known as
triptolide, which has been identified as a cancer fighter in
previous research, it is thought to be the key component that may
be responsible for the anti-tumor capabilities.  
  
Study leader and vice chairman of research at the Cancer Center
explained to Bloomberg how he was blown away by the effects of the
simple plant:  
  
This drug is just unbelievably potent in killing tumor cells, he
said.  
  
And just like with numerous other powerful substances like
turmeric and ginger, mainstream science is still slowly confirming
what many traditional practitioners have known for their entire
lives. This is, of course, due to the fact that there is simply no
money for major corporations in researching the healing powers of
natural herbs and compounds such as the compound found in the
thunder god vine. Turmeric and ginger, for example, have been
found to be amazing anti-cancer substances that are virtually free
compared to expensive and dangerous cancer drugs.  
  
Nevertheless, the Big Pharma sponsored corporate scientists have
managed to ignore these spices as much as possible. In fact, they
have even been caught time and time again faking thousands of
studies to fraudulently demonstrate the supposed value of
pharmaceutical drugs pushed by major pharma juggernauts  many of
which are later forced to pay millions in fines which only
slightly stack up against their billions in profits.  
  
Profits that are threatened by the many real studies that were
performed by scientists examining the rejeuvenating power of cheap
ingredients like turmeric, which has been found by peer-reviewed
research available on PubMed to positively influence over 590
conditions.  
  
While it is great news that this study is bringing the beneficial
effects of inexpensive and near-free plant compounds to light, the
bad news is that the individuals responsible for the research are
actually looking to create a pharmaceutical drug from the
essential component triptolide. A drug that will seek FDA approval
and ultimately be patented, nutritionally ruined, and sold for
exorbitant amounts of cash. Instead, just get your hands on some
thunder god vine for yourself.  
  


---

  
[**http://www.bloomberg.com/news/2012-10-17/drug-from-chinese-thunder-god-vine-slays-tumors-in-mice.html**](http://www.bloomberg.com/news/2012-10-17/drug-from-chinese-thunder-god-vine-slays-tumors-in-mice.html)

**Drug From Chinese Thunder God Vine
Slays Tumors in Mice**  
  
**By**   
  
**Drew Armstrong**

  
A drug made from a plant known as thunder god vine, or lei gong
teng, that has been used in traditional Chinese medicine, wiped
out pancreatic tumors in mice, researchers said, and may soon be
tested in humans.  
  
Mice treated with the compound showed no signs of tumors after 40
days or after discontinuing the treatment, according to
researchers at the University of Minnesotas Masonic Cancer
Center. The research, funded by the university and the National
Institutes of Health. was published today in the journal*Science Translational Medicine.*  
This drug is just unbelievably potent in killing tumor cells,
said Ashok Saluja, vice chairman of research at the center and the
studys leader, said in a telephone interview. You could see that
every day you looked at those mice, the tumor was decreasing and
decreasing, and then just gone.  
  
The plant, also known as *Tripterygium wilfordii*, contains
triptolide, which earlier studies have shown can cause cancer
cells to die. In traditional Chinese medicine, the plant is used
as a treatment for rheumatoid arthritis. While the researchers
hope to start human trials in six months, Saluja said its still a
long leap from mice to people.  
  
Does that mean it will definitely work in humans? he said. We
can definitely not say that.  
  
The results pave the way for clinical trials in patients with
pancreatic cancer, one of the most lethal malignancies, the
researchers said in the study. About 44,000 new cases of the
disease are diagnosed each year in the U.S., according to the U.S.
Centers for Disease Control and Prevention in Atlanta. Only about
20 percent of patients survive a year after diagnosis, Saluja
said.  
  
**Survival Odds**  
Even for patients diagnosed at the earliest stages of their cancer
when the odds are better, only about 14 percent survive five years
or longer, according to the American Cancer Society. The current
treatment is Eli Lilly & Co.s Gemzar (LLY), which sold $452
million last year. A generic version of the drug became available
in 2011, according to data compiled by Bloomberg.  
  
It adds six weeks -- its nothing, Saluja said. Theres
definitely a need to discover and develop more strategies for
pancreatic cancer.  
  
The researchers dubbed the drug Minnelide, a combination of
Minnesota and triptolide. They developed a water soluble version
that could be injected into mice, and in the future administered
to patients intravenously.  
  
Saluja and his group have formed a company, Minneamrita
Therapeutics, which will attempt to take the drug into the first
of three stages of human clinical trials that are generally
required before U.S. regulatory approval. Saluja said the company
has discussed the trials with the Food and Drug Administration.  
  


---

  
[**http://nccam.nih.gov/health/tgvine**](http://nccam.nih.gov/health/tgvine)

**Thunder God Vine**

Common Names: thunder god vine, lei gong teng  
Latin Name: Tripterygium wilfordii  
  
**Introduction**  
This fact sheet provides basic information about thunder god vine
 common names, what the science says, potential side effects and
cautions, and resources for more information.  
  
Thunder god vine is a perennial vine native to China, Japan, and
Korea. It has been used in China for health purposes for more than
400 years. In traditional Chinese medicine, it has been used for
conditions involving inflammation or overactivity of the immune
system. Currently, thunder god vine is used as a traditional or
folk remedy for excessive menstrual periods and autoimmune
diseases, such as rheumatoid arthritis, multiple sclerosis, and
lupus.  
  
Extracts are prepared from the skinned root of thunder god vine.  
  
**What the Science Says**  
Laboratory findings suggest that thunder god vine may fight
inflammation, suppress the immune system, and have anti-cancer
effects.  
  
Although early evidence is promising, there have been few
high-quality studies of thunder god vine in people. Results from a
large study funded by the National Institute of Arthritis and
Musculoskeletal and Skin Diseases (NIAMS), which compared an
extract of thunder god vine root with a conventional medicine
(sulfasalazine) for rheumatoid arthritis, found that participants
symptoms (e.g., joint pain and swelling, inflammation) improved
more significantly with thunder god vine than with sulfasalazine.  
  
A small study on thunder god vine applied to the skin found
benefits for rheumatoid arthritis symptoms.  
  
There is not enough scientific evidence to assess thunder god
vines use for any other health conditions.  
  
**Side Effects and Cautions**  
Thunder god vine can cause severe side effects and can be
poisonous if it is not carefully extracted from the skinned root.
Other parts of the plantincluding the **leaves, flowers, and
skin of the rootare highly poisonous** and can cause death.  
  
A number of participants in the NIAMS study experienced
gastrointestinal adverse effects such as **diarrhea,
indigestion, and nausea, as well as upper respiratory tract
infections**. (The rate of adverse effects was similar in the
thunder god vine and sulfasalazine groups.)  
  
**Thunder god vine can also cause hair loss, headache, menstrual
changes, and skin rash.**  
  
There are no consistent, high-quality thunder god vine products
being manufactured in the United States. Preparations of thunder
god vine made outside the United States (for example, in China)
can sometimes be obtained, but it is not possible to verify
whether they are safe and effective.  
 **Thunder god vine has been found to decrease bone mineral
density in women who take the herb for 5 years or longer**.
This side effect may be of particular concern to women who have
osteoporosis or are at risk for the condition.  
  
Thunder god vine contains chemicals that might decrease male
fertility by changing sperm.  
  
Tell all your health care providers about any complementary health
practices you use. Give them a full picture of what you do to
manage your health. This will help ensure coordinated and safe
care. For tips about talking with your health care providers about
complementary and alternative medicine, see NCCAM's Time to Talk
campaign.  
  
**Sources**  
Canter PH, Hyang SL, Ernst E. A systematic review of randomized
clinical trials of Tripterygium wilfordii for rheumatoid
arthritis. Phytomedicine. 2006;13(5):371377.  
  
Carter BZ, Mark DH, Schober WD, et al. Triptolide induces
caspase-dependent cell death mediated via the mitochondrial
pathway in leukemic cells. Blood. 2006;108(2):630637.  
  
Goldbach-Manksy R, Wilson M, Fleischmann R, et al. Comparison of
Tripterygium wilfordii Hook F versus sulfasalazine in the
treatment of rheumatoid arthritis: a randomized trial. Annals of
Internal Medicine. 2009;151(4):229240, W4951.  
  
National Center for Complementary and Alternative Medicine.
Rheumatoid Arthritis and CAM. National Center for Complementary
and Alternative Medicine Web site. Accessed at
nccam.nih.gov/health/RA/getthefacts.htm on June 3, 2010.  
  
National Institute of Arthritis and Musculoskeletal and Skin
Diseases. Chinese Thunder God Vine Gives Relief from Rheumatoid
Arthritis Symptoms. National Institute of Arthritis and
Musculoskeletal and Skin Diseases Web site. Accessed at :  
  
www.niams.nih.gov/News\_and\_Events/Spotlight\_on\_Research/2002/thunder.aspon  
 June 3, 2010.  
  
Setty AR, Sigal LH. Herbal medications commonly used in the
practice of rheumatology: mechanisms of action, efficacy, and side
effects. Seminars in Arthritis and Rheumatism. 2005;34(6):773784.  
  
Tao X, Younger J, Fan FZ, et al. Benefit of an extract of
Tripterygium wilfordii Hook F in patients with rheumatoid
arthritis: a double-blind, placebo-controlled study. Arthritis
& Rheumatism. 2002;46(7):17351743.  
  
Thunder god vine. Natural Medicines Comprehensive Database Web
site. Accessed at : www.naturaldatabase.com on September 15, 2009.  
  
**NCCAM Clearinghouse**  
The NCCAM Clearinghouse provides information on NCCAM and
complementary health approaches, including publications and
searches of Federal databases of scientific and medical
literature. The Clearinghouse does not provide medical advice,
treatment recommendations, or referrals to practitioners.  
  
Toll-free in the U.S.: 1-888-644-6226  
TTY (for deaf and hard-of-hearing callers): 1-866-464-3615  
Web site: nccam.nih.gov  
E-mail: info@nccam.nih.gov  
  
A service of the National Library of Medicine (NLM), PubMed(r)
contains publication information and (in most cases) brief
summaries of articles from scientific and medical journals.  
  


---

  
[**http://www.ncbi.nlm.nih.gov/pubmed/12124856**](http://www.ncbi.nlm.nih.gov/pubmed/12124856)

**Benefit of an extract of Tripterygium
Wilfordii Hook F in patients with rheumatoid arthritis:   
a double-blind, placebo-controlled study.**

**Tao X, Younger J, Fan FZ, Wang B, Lipsky
PE.**

**Source****Autoimmunity Branch, National Institute of Arthritis and
Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland
20892, USA.****Abstract****OBJECTIVE:**  
To examine the safety and efficacy of an extract of Tripterygium
wilfordii Hook F (TWHF) in the treatment of patients with
rheumatoid arthritis (RA).  
  
**METHODS:**  
An ethanol/ethyl acetate extract from the roots of TWHF was
prepared and used in a prospective, double-blind,
placebo-controlled study in patients with longstanding RA in whom
conventional therapy had failed. Patients were randomly assigned
to receive either placebo or low-dose (180 mg/day) or high-dose
(360 mg/day) extract for 20 weeks, followed by an open-label
extension period. Clinical responses were defined as 20%
improvement in disease activity according to the American College
of Rheumatology criteria. Side effects were actively queried and
recorded at each visit.  
  
**RESULTS:**  
A total of 35 patients were enrolled in the trial; 21 patients
completed the 20-week study. One patient from each group withdrew
because of side effects. Twelve, 10, and 10 patients in the
placebo, low-dose, and high-dose groups, respectively, completed
at least 4 weeks of treatment. Of these patients, 8 and 4 in the
high-dose and low-dose groups, but none in the placebo group, met
criteria for clinical response. Four, 4, and 7 patients in the
placebo, low-dose, and high-dose groups, respectively, were
enrolled in the open-label extension; of these, 2, 4, and 5
patients, respectively, met criteria for clinical response. The
most common side effect was diarrhea, which caused 1 patient in
the high-dose group to withdraw from the trial. No patients
withdrew because of adverse events during the open-label
extension.  
  
**CONCLUSION:**  
The ethanol/ethyl acetate extract of TWHF shows therapeutic
benefit in patients with treatment-refractory RA. At therapeutic
dosages, the TWHF extract was well tolerated by most patients in
this study.  
  


---

  
[**http://www.sciencedirect.com/science/article/pii/S0031942207001203**](http://www.sciencedirect.com/science/article/pii/S0031942207001203)

**Anti-inflammatory and
immunosuppressive compounds from Tripterygium wilfordii**  
  
**Jun Maa, et al.**

  
**Abstract**  
The extract of Tripterygium wilfordii Hook F. (TwHF), which showed
anti-inflammatory and immunosuppressive activities in human
clinical trials for rheumatoid arthritis, was subjected to the
activity-guided fractionation and spectroscopic characterization
of bioactives. A tetrahydrofuran lignan, tripterygiol (1), and
eight known compounds, all capable of suppressing pro-inflammatory
gene expression were identified. Most of the pharmacological
activity of the extract can be attributed to triptolide, its most
abundant and active component, with some contribution from
tripdiolide.  
Graphical abstract  
  
A tetrahydofuran lignan, tripterygiol (1), and eight known
compounds, were isolated and structurally characterized from the
ethyl acetate extract of Tripterygium wilfordii which was proven
active in a clinical trial for the rheumatoid arthritis. All
isolated compounds inhibited expression of pro-inflammatory genes
in mouse macrophages.  
  


---

**PATENTS**  

**US2012238529**  
**TRIPTOLIDE PRODRUGS**

  
**( Excerpts )****Inventor: GEORG INGRID GUNDA // PATIL SATISH PRAKASH**

![](prodrug2.jpg)  
  
  
![](prodrugtumor2.jpg)

**BACKGROUND OF THE INVENTION**  
[0001] Pancreatic cancer is a particularly aggressive and
devastating disease with a five-year survival rate of less
than 5%. No effective drug treatment is currently available
which can effectively prolong patient survival. In 2006,
over 35,000 new pancreatic cancer cases were reported with
an almost equal number succumbing to the disease. Resistance
to apoptosis has been investigated as a key factor in
preventing response in patients to therapies to treat
pancreatic and other cancers.  
  
[0002] Triptolide is a naturally occurring compound obtained
from the plant Tripterygium wilfordii. Triptolide is known
to be useful in treating autoimmune diseases,
transplantation rejection (immunosuppression), and possesses
anticancer and anti-fertility effects as well as other
biological effects (Qui and Kao, 2003, Drugs R. D. 4, 1-18).
Triptolide has strong antitumor effects against xenograft
tumors (for example, Yang et al. Mol. Cancer. Ther, 2003, 2,
65-72). Triptolide is an anti-apoptotic agent with multiple
cellular targets that are implicated in cancer growth and
metastasis. Triptolide inhibits NF-kB activation, induces
bid cleavage, blocks induction of the survival gene p21
WAF1/<Cip1 >(Wang et al. Journal of Molecular
Medicine, 2006, 84, 405-415) and inhibits the function of
heat shock transcription factor 1 (HSF1) thereby suppressing
endogenous Hsp70 gene expression (Westerheide et al. 2006,
Journal of Biological Chemistry, 281, 9616-9622). Triptolide
also functions as a potent tumor angiogenesis inhibitor (He
et al. 2010, Int. Journal of Cancer, 126, 266-278).  
  
[0003] Several mechanisms exist in living cells that protect
against adverse conditions, including cancer cells. The
synthesis of a family of proteins referred to as heat-shock
proteins (HSPs) is one such protective mechanism. Major HSPs
include HSP90, HSP70, HSP60, HSP40 and smaller HSPs. HSPs
can be present in most intracellular compartments, with
HSP70 being primarily located in cytosol.  
  
[0004] Dysregulated expression of HSP70 is known to be
associated with many diseases including cancers. HSP70 is
abundantly expressed in malignant tumors of various origins
(For example: Hantschel et al. 2000, Cell Stress Chaperones,
5, 438-442), which render the tumor cells resistant to
therapy and poor prognosis for the patient (Fuqua et al.
1994, Breast Cancer Res, Treatment 32, 67-71). Heat shock
protein 70 (Hsp70) is known to be upregulated and
over-expressed in pancreatic cancer cells as compared to
normal cells. Furthermore, HSP70 has a protective effect on
cancer cells inhibiting apoptosis of the cells. Inhibition
of HSP70 in pancreatic cancer cells has been shown to
increase apoptic cell death of these cells (See for example
Aghdassi et al., Cancer Research, 67(2) p. 616-625 (2007)).
Triptolide has been shown to inhibit pancreatic tumor growth
and metastasis in mice. It was also shown that triptolide
when used in combination with ionization radiation its
therapeutic effect in pancreatic cancer treatment is
enhanced (Wang et al. Proc. Amer. Assoc. Cancer Res. 2006,
47, abstract #4720 and Wang et al. Clin. Cancer Res. 2007,
13, 4891-4899). It is believed that the anticancer effect
associated with triptolide occurs as a result of reducing
levels of the protein HSP70 expressed in significant amounts
by pancreatic cancer cells as compared to normal pancreatic
cells. Thus, triptolide therapies have been of interest in
the medical field for their potential treatment of cancers
that over-express HSP70, including pancreatic cancer. See
for example, Phillips et al., Cancer Research, 67(19), p.
9407-16 (2007).  
  
[0005] There are, however, certain disadvantages associated
with administering triptolide and different solutions to
address these problems have been explored. One problem
associated with native triptolide is that it is insoluble in
aqueous solution. Another problem associated with natural
triptolide is poor bioavailability and toxic side effects.
Triptolide, triptolide derivatives and certain prodrugs
having improved solubility and reduced toxicity are known.
For example, Dai et al. U.S. Pat. No. 6,548,537 describes
triptolide prodrugs having increased solubility and reduced
toxicity.  
  
[0006] The phosphonoxymethyl moiety per se is known in the
art for purposes of forming prodrug compounds of certain
pharmaceutical compounds. For example, Krise et al., J. Med.
Chem., 42, pp. 3094-3100 (1999) describes preparation of
N-phosphonooxymethyl prodrugs of certain compounds to
improve water solubility.  
  
[0007] Nevertheless, prodrugs must possess a number of
properties in order to be practically useful. For instance,
desirable prodrugs should be stable for formulation and
administration. Additionally, once administered and present
in the recipient's system, the prodrug must be successfully
activated. Furthermore, both the prodrug and activated
compound must be compatible with biological fluids, such as
plasma and tissue homogenates. Ultimately, the activated
compound initially delivered in prodrug form must have its
desired therapeutic or pharmaceutical effect. These and
other factors can be difficult to achieve simultaneously, or
collectively balance, with certain types of compounds.
Within the context of triptolide and triptolide prodrug
compounds it has been difficult achieve improved aqueous
solubility, effective bioavailability for oral dosage forms,
faster in vivo release of triptolide, and relatively reduced
or lower toxicity in combination with significant inhibition
of cancer cell growth. For example, see Chassaing et al.,
Highly Water-Soluble Prodrugs of Anthelminthic Benzimidazole
Carbamates: Synthesis, Pharmacodynamics and
Pharmacokinetics, J. Med. Chem., 51(5), pp. 1111-1114
(2008).  
  
[0008] Succinate prodrug forms of triptolide are known, but
have been associated with certain disadvantages. See, for
example, Harrousseau et al., Haematologica 2008, 93(s1), 14
Abstract 0038 and Kitzen et al. European Journal of Cancer
2009, 45, 1764-1772. Incomplete and variable conversion of
the succinate prodrug of triptolide has been observed.  
  
[0009] Thus, there exists a need in the medical and
pharmaceutical fields for improved therapeutics for treating
cancers including aggressive solid tumor cancers, such as
pancreatic cancer. There also exists a further need for
improved delivery or improved pharmacokinetic parameters or
reduced toxicity of such therapeutics. There also exists a
need for prodrug forms of triptolide that have improved
solubility or that have faster release of the active
compound triptolide or that have a more therapeutically
effective release of the active compound triptolide or for
prodrug forms of triptolide with improved bioavailability.  
  
**BRIEF DESCRIPTION OF THE FIGURES****[0025] FIG. 1 illustrates a chemical reaction diagram
for preparing the compound 1.****DETAILED DESCRIPTION OF THE INVENTION**[0119] Triptolide is used to treat a variety of diseases
such as inflammatory diseases. Triptolide has also been
implicated as a therapeutic agent to treat a variety of
diseases. These diseases include cancer (e.g. pancreatic
cancer, bile duct carcinoma, neuroblastoma, colon cancer,
breast cancer, myeloma, gastric cancer, liver cancer,
glioblastoma, ovarian cancer, colorectal cancer, non-Hodgkin
lymphoma, lung cancer, prostate cancer, small-cell lung
cancer, large cell lung cancer, kidney cancer, esophageal
cancer, stomach cancer, cervical cancer, lymphoma tumors),
autoimmune diseases, transplant rejection, polycystic kidney
disease, inflammatory diseases, asthma, rheumatoid
arthritis, systemic lupus erythematosus and nephritis.
Triptolide has also been discussed in the coating of stents
(drug elution), spinal cord repair, colitis, and
contraception in male and female animals. Accordingly, the
invention includes but is not limited to the use of the
compounds of formula I to treat diseases including cancer
(e.g. pancreatic cancer, bile duct carcinoma, neuroblastoma,
colon cancer, breast cancer, myeloma, gastric cancer, liver
cancer, glioblastoma, ovarian cancer, colorectal cancer,
non-Hodgkin lymphoma, lung cancer, prostate cancer,
small-cell lung cancer, large cell lung cancer, kidney
cancer, esophageal cancer, stomach cancer, cervical cancer,
lymphoma tumors), autoimmune diseases, transplant rejection,
polycystic kidney disease, inflammatory diseases, asthma,
rheumatoid arthritis, systemic lupus erythematosus and
nephritis. Compounds of formula I can also be can also be
used for coating stents (drug elution), spinal cord repair,
colitis, and contraception in male and female mammals.  
  
[0120] The following documents are directed to triptolide
and cancer (1. AML: Carter et al., Blood, 2008, 111(7),
3742-3750. 2. Anaplastic thyroid carcinoma: Mol. Pharmacol.,
2009, 75(4), 812-9. 3. Bladder cancer: Yang et al., Mol.
Cancer. Ther., 2003, 2(1), 65-72. 4. B16 Melanoma: Yang et
al., Mol. Cancer. Ther. 2003, 2(1), 65-72. 5. Breast Cancer:
Liang et al., Cancer Letters, 270(2), 2008, 337-341. Liu et
al., Phytomedicine, 2009, 16(11), 1006-1013. 6. Cervical
Cancer Wang et al., J. Mol. Med., 2006, 84(5),405-15. 7.
Cholangiocarcinoma: Tengchaisri et al., Cancer Letters,
1998, 133(2), 169-175. 8. CML: Lou et al., Leukemia and
Lymphoma, 2004, 45, 373-376. 9. Colon: Tang et al.,
Postgraduate Medical Journal 2007, 83, 338-343. 10.
Esophageal cancer: Boult et al., B. J. Cancer, 2008, 89,
1985-92. 11. Fibrosarcoma: Kiviharju et al., Clinical Cancer
Research, 2002, 8, 2666-2674. 12. Miyata et al., Biochem.
Biophys. Res. Commun., 2005, 336(4), 1081-6. 13. Gastric
Cancer: Jiang., Oncogene, 2001, 20(55), 8009-18. 14. Yang et
al., Mol. Cancer. Ther. 2003, 2(1), 65-72. 15. Glioblastoma
Multiforme Lin et al., J. Int. Med. Res., 2007, 35(4),
490-6. 16. Kapoor, Int. J. Mol. Med., 2008, 22(4), 489-96.
17. Human Prostatic Epithelial Cells: Kiviharju et al.,
2002., Clinical Cancer Research, 8, 2666-2674. 18. Leukemias
including AML: Carter et al., Blood, 2006, 108(2), 630-7.
19. Multiple myeloma: Yinjun et al., Leuk. Res. 2005 29(1),
99-105. 20. Neuroblastoma: Antonoff et al., Surgery, 2009,
146(2), 282-90.  
  
[0000] 21. non-Hodgkin lymphoma: Zhang et al., Acta
Pharmacologica Sinica, 2006, 27, 1438-1446. 22. Non-small
cell lung cancer: Chang et al., The Journal of Biological
Chemistry, 276, 2221-2227. 23. Osteosarcoma: Wang et al.,
Pediatr. Blood Cancer. 2008, 51(6), 754-9. 24. Ovarian
Cancer: Westfall et al., Chemotherapy, 2008, 54(1), 67-76.
25. Pancreatic Cancer: Wang et al., J. Mol. Med. 2006,
84(5), 405-15., Zhou et al., World J., Gastroenterol, 2008,
14(10), 1504-1509., Wang et al. Clincal Cancer Research
2007, 13, 4891., Phillips, Saluja et al., Cancer Res., 2007.  
  
Squamous cell carcinoma; Miyata et al., Biochem. Biophys.
Res. Commun., 2005, 336(4), 1081-6. 26. Thyroid carcinoma:
Zhu et al., Oncol Rep., 2009, 22(6),1397-401. 27. Uterine
cervical carcinoma: Miyata et al., Biochem. Biophys. Res.
Commun., 2005, 336(4), 1081-6. 28. Urothelial Cancer Matsui
et al., Oncogene, (2008) 27, 4603-4614).  
  
[0121] The following documents are directed to triptolide
and diseases other than cancer (1. Multiple diseases: D Qui
et al., Drug R & D, 2003, 4, 1-16.  
  
[0000] 2. Organ transplantation: Chen, Leukemia and
Lymphoma, 2001, 42, 253-256.  
3. Kidney transplant: Zhang et al., Journal of
Ethnopharmacology, 2009, 125(1), 141-46. 4. Transplantation
graft survival (skin): Yang et al. Int. J. Immunophamac.,
1992, 14, 963-969. 5. Graft-Versus-Host disease: Chen et
al., Transplantation, 2000, 70, 1442-1447. 6. Inflammatory
and autoimmune diseases: P. E. Lipsky et al., Seminars in
Arthritis and Rheumatism, 1997, 5, 713-723. 7. Autoimmune
encephalomyelitis: Kizelsztein et al. Journal of
Neuroimmunology, 2009, 217, 28-37. 8. Cerebral
ischemia/reperfusion injury: Wei et al., Neural Regeneration
Research, 2007. 9. Colitis: Wei et al., Clin. Immunol. 2008,
129, 211-218. 10. Contraception in males and females: Hikim
et al., Journal of Andrology, 2000, 21, 431-437., Huynh et
al., Journal of Andrology, 2000, 21, 689-699., Wang et al.,
Asian Journal of Andrology, 1999, 1, 121-125., Lue et al.,
Journal of Andrology, 1998, 19, 479-486. 11. Corneal ulcer:
Lu et al. Investigative Ophthalmology and Visual Science.
2006, 47, 3796-3800. 12. Lung inflammation: Krishna, et al.,
2001, Am. J. Pathol., 2001, 158(3), 997-1004. 13. Nephritis:
Tao et al., Arthritis Rheum. 2008, 58(6), 1774-83. 14.
Parkinsonism and neuroprotection: Zhou et al., Neurobiology
of Disease, 2005, 18, 441-449. 15. Polycystic kidney disease
(PKD): Leuenroth et al., PNAS, 2007, 104, 4389-4394. 16.
Spinal cord repair: Su et al., Glia 2010, 58, 901-915. 17.
Stent coating: Q. Luo 2005, Patent application 20050043788).  
  


---

 **Application of triptolide in preparation of medicament
for treating or preventing human immunodeficiency viruses
(HIV)**   
**CN102755335**

 **Abstract**  
The invention discloses an application of triptolide in
preparation of a medicament for treating or preventing human
immunodeficiency viruses (HIV). The triptolide is diterpenoid
naturally existing in roots of tripterygium wilfordii hook, and
can dose-dependently inhibit replication of I type HIV (HIV-1) in
cells in vitro. The half inhibitory concentrations on HIV-1
inhibition in TZM-b1 cells, JurkatT lymphocytes and human
peripheral blood mononuclear cells are respectively 0.32nM, 0.45nM
and 1.1nM. The triptolide has a remarkable inhibiting effect on
the replication of the HIV-1 in the TZM-b1 cells, the JurkatT
lymphocytes and the human peripheral blood mononuclear cells; and
the triptolide is an active ingredient in Chinese medicinal
tripterygium wilfordii hook, so the triptolide is wide in source.
The compound has a broad prospect for developing anti-HIV-1
medicaments.  
  


---

  

**Triptolide purification method**  
**CN1876656**

**Abstract**  
The invention discloses a method for using a diterpene lactone
compound of tripterygium in the treatment of cancers. The
diterpene lactone compound comprises diterpene lactone alcohol of
tripterygium, diterpene lactone glycol of tripterygium, diterpene
lactone ketone of tripterygium and a plurality of derivatives of
the diterpene lactone alcohol of tripterygium.  
  
**Technology**  
The invention relates to the field of traditional Chinese medicine
preparation technology, in particular to a method for purifying
triptolide.  
  
**BACKGROUND**  
Triptolide (triptolide), that triptolide, is one of the main
components of triptolide, which is immunosuppressive Tripterygium
preparations the main active ingredient, but also the toxic
components in the current Chinese medicine preparation for its
content There are strict controls.  
  
Since triptolide to effective dose and toxic dose is very close to
the possibility of developing new drugs basic single component is
negated.  
  
However, as an effective lead drug (lead drug), nearly 20 years,
domestic and foreign pharmaceutical scientists are constantly
screening triptolide derivatives, and made a lot of encouraging
progress.  
  
For potential new drug development triptolide derivatives, parent
structure of triptolide preparation and supply is a more realistic
and urgent problem.  
  
On the current research, the total synthesis of triptolide can not
yet reached the level of practical application, that is currently
a prime raw material is generally isolated from the plant extract.  
  
Triptolide in Tripterygium wilfordii or were very low in content,
generally between 10 ~ 30ppm, while by solvent extraction,
purified extract of routine, the A pigment content is not high,
usually in a % down.  
  
If this and other quality of extract directly on column
chromatography A hormone, the efficiency of the preparation work
is definitely lower, and the cost is quite expensive and not
conducive to possible future industrial production.  
  
Therefore, how the use of economic, reasonable method or from
Tripterygium wilfordii extract triptolide has been plagued by
people of a problem.  
  
**SUMMARY OF THE INVENTION**  
The present invention is to solve the technical problem is the use
of simple and economical method of purifying the extract greatly
increased Tripterygium triptolide content of the preparation of
high purity triptolide possible.  
  
The invention discloses triptolide purification method is based on
extracts of Tripterygium ordinary material, solvent and dispersion
by adding adsorbents, sufficiently adsorbed, filtered,
concentrated and dried to obtain a purified extract of
Tripterygium wilfordii extract.  
  
The preferred purification method of the present invention is as
follows:  
  
Take 1 part of a commercially available extract of Tripterygium
general, add 3 to 10 parts of the adsorbent, with the vehicle at
30 ~ 50 ?, stirring to dissolve extract is then filtered, the
filter cake was washed several times with fresh solvent, the use
of the total solvent extract the amount of 15 to 30 times the
amount of the combined filtrate and washings were concentrated and
dried to obtain a purified extract of Tripterygium wilfordii
extract powder.  
  
The present invention a commercially available extract of
Tripterygium common is the use of conventional methods wilfordii
extract obtained by extraction, which triptolide content of about
1%.  
  
Said adsorbent is selected from silica gel, neutral alumina,
diatomaceous earth, cellulose and other commonly used adsorption
media.  
  
Said solvent is selected from lower aliphatic hydrocarbons, lower
aliphatic ketones, esters, halogenated lower alkyl or a mixture
thereof.  
  
Method of the present invention is to obtain a purified extract
yield of about 50%, by HPLC assay, which triptolide content of
about 2%, triptolide component transfer rate of 95% or more.  
  
Since triptolide in traditional Chinese medicine Tripterygium
wilfordii or very low content of both, so its extraction and
separation process, efforts to improve the process every step of
triptolide component of the actual transfer rate is especially
important.  
  
By column chromatography, triptolide there are some irresistible
adsorption losses, with the absorbent material used in the
different nature of triptolide component transfer rate is
generally 60 to 85%, so the actual industrial production, should
minimize the number of times by column chromatography in order to
maximally reduce the loss of a prime ingredient to improve the
preparation of the actual production yield.  
  
The present invention addresses the above separation
characteristics of triptolide to diversify Tripterygium extract
adsorption treatment method, and achieved satisfactory results.  
  
Adsorption method with regard to the dispersion characteristics of
column chromatography is shown in table 1.  
  
**Table 1.****Dispersion and adsorption column chromatography separation
A prime feature comparison**  
As can be seen from the above comparison, the present invention is
a commercially available extract of Tripterygium as raw material,
using conventional column chromatography adsorbent material
dispersion of non-adsorption process, and the resulting purified
extract volume reduced by half, and its triptolide content
doubled.  
  
Biggest advantage of this method is simple to prepare and shorter,
triptolide metastasis rate and solvent usage and other small
features, a more realistic approach by the extract of the
invention, in a subsequent row column chromatography A prime time
, the interference of impurities greatly reduced, as the ultimate
easy access to high-purity triptolide foundation.  
  
**BRIEF DESCRIPTION**  
**Figure 1 Example 1 Product HPLC chart****Figure 2 triptolide reference HPLC chart****Specific embodiments****Example 1**Take Tripterygium extract (triptolide content 1%) 2kg, 12kg
silica gel, chloroform was added 15kg, under heat at 30 ?
sufficiently stirred to extract fully dissolved, and then
filtered, the filter cake was washed several times with
chloroform, chloroform Total amount of 30kg.  
  
Combined chloroform solution, reduced dry purified extract of
Tripterygium 0.9kg, triptolide its content is 2.2% (HPLC method)
in Figure 1, Figure 2 triptolide reference.  
  
**Example 2**  
Tripterygium wilfordii extract taken 1kg (triptolide content of
1%), neutral alumina 5kg, ethyl acetate was added 10kg, incubated
at 40 ? under stirring and dissolved extract is then filtered cake
was washed with the remaining 5kg washed several times with ethyl
acetate, the combined ethyl acetate filtrate and washings were
concentrated in vacuo and dried to yield purified extract 0.5kg,
its triptolide content of 2.0%.  
  
**Example 3**  
Tripterygium wilfordii extract taken 1kg (triptolide content of
1%), diatomaceous earth 10kg, 15kg with acetone - cyclohexane
(1:1), stirred at 35 ? sufficiently dissolved extract, then
filtered, the filter cake 10kg was washed several times with the
solvent, the combined filtrate and washings were concentrated in
vacuo and dried to yield purified extract 0.6kg, triptolide
content of which was 1.7%.  
      


---

  

**Method for planting Chinese herb
triperygium wilfordii**  
**CN1994044**

  
The invention relates to a method for planting Tripterygium
wilfordii, wherein said method comprises that: 1, collecting 1-2
year old branch, cutting into 10-15cm branches, while each section
has 3-4 nodes; 2, putting low end of branch into 500-1000ppm
alpha-fruitone or indolebutyric acid solution, taking out and
drying to be incline inserted into the seed bed, pouring water; 3,
planting seeds 60-90cm distance, and 800-1000n/km; 4, fertilizing
after spring, at June and July, spraying 0.3% monobasic potassium
phosphate, at October and December, spraying organic fertilizer;
5, when the seed flowers, on time taking out bulb, at May to
September, when grows to 40-60cm, cutting top bulb; 6,
transplanting, harvesting after 2 or 3 years.  
  
**DESCRIPTION**  
**Technology**  
The present invention relates to a method of traditional Chinese
medicine Tripterygium planting.  
  
**BACKGROUND**  
Hook, alias Gelsemium elegans, yellow vine, yellow wax vine,
vegetable insecticide, etc. for Tripterygium Celastraceae species,
deciduous vine-like shrub.  
  
Currently used as medicine, there are three original plant
Tripterygium: triptolide Tripterygiumwilfordii Hook.f., KMSHT
T.hypogeaucum (Leve) Hutch. And the Black Man (Northeast TWH)
T.regeli Sprague et Tak..  
  
Hook the root medicine, cold, bitter, big drug has medicinal
properties, Qufengchushi, swelling and pain effect, modern
pharmacological study found that triptolide has anti-inflammatory,
antibacterial, anti-fertility, anti-tumor, immune suppression
effect, as well as lifting of the blood pool, reduce blood
viscosity, improve microcirculation and reduce the role of the
resistance of peripheral blood, attending rheumatoid arthritis,
lupus, chronic nephritis, nephrotic syndrome and allergic skin
diseases disease.  
  
Isolated from Tripterygium has 70 kinds of chemical monomers which
two terpene lactones as the main active ingredient, as well as
three terpenes, alkaloids, sesquiterpenes and other chemical
ingredients.  
  
Natural state, Hook wild in the subtropical region, located in the
provinces south of the Yangtze River to the southwest, such as
Hunan, Hubei, Jiangxi, Anhui, Zhejiang, Fujian, Guangdong, Guangxi
and Taiwan provinces.  
  
Grown at an altitude of more than 300 ~ 500m sunny, humid,
slightly fertile valleys, hills, stream thickets, woodland.  
  
Warm and humid climate, generally grown in well-drained, pH5 ~ 6
slightly acidic sandy loam or red loam.  
  
**SUMMARY OF THE INVENTION**  
The purpose of the present invention is to provide a traditional
Chinese medicine Tripterygium cultivation methods.  
  
Comprising the steps of:  
  
1) cuttage  
  
(A) Acquisition 1 to 2 years old, robust, no pests branches, cut
into 10 ~ 15cm long cuttings, each with three to four sections,
the cuttings tied into bundles, or takes more than 3 years
triptolide kinds of roots, clipping diameter 0.2 ~ 4cm, length 10
~ 15cm seed roots, spare;  
  
(2) into the bottom of the prepared cuttings 500 ~ 1000ppm of
a-NAA or IBA solution immersed, remove a little dry Xiecha the
prepared seedbed, or on the prepared kind of root Xiecha segment
on the prepared seedbed, buried 1/2 to 2/3, inserted immediately
after watering, cover film, surrounded by soil compaction;  
  
2) colonization  
  
(A) in the year in November to next March planting, spacing 60 ~
90cm, with a volume of 800 to 1000 seedlings / acre, planted in
well-drained pH 5 to 6 slightly acidic red loam or silt soil class
;  
  
(2) when planted in the furrow opening 60 ~ 90cm x 60 ~ 90cm of
the   
planting hole, depth 40 ~ 50cm, planted one per hole, planting
seedlings root system will start righting seedlings, while gently
lifting the edge of the casing seedlings, casing to cover no
roots, compaction;  
  
(3) Every fertilizing before planting organic fertilizer products
100 ~ 300g, ash 200 ~ 400g, rapeseed fat 15 ~ 45g.  
Cast basal fertilizer, seedling roots and then to high overburden
portion 5cm, compaction, irrigated;  
  
3) fertilization  
  
In the spring of each year after birth, a new little pumping,
combined with weeding, applying fertilizer on potassium
chloride-based chemical plants around the root, 15 ~ 20kg / acre,
in July and August, the election evening or cloudy, spraying 0.3%
phosphate potassium, 50kg / acre, in October and November, the
plant four weeks at 20 ~ 30cm ring ditch, applied into organic
fertilizer products, 400 ~ 600kg / acre;  
  
4) field management  
  
(A) in the June to August Hook flowering, election sunny, timely
removal of buds, check once every 10d.  
  
(2) in May to September, the election sunny, slightly longer in
the new time to 40 ~ 60cm, pruning or removal of the terminal bud,
check once every 20d.  
  
5) cuttings after transplanting, harvesting two to three years.  
The present invention NAA or IBA reagent cuttings, branches can
promote triptolide rooting cuttings improve the survival rate for
the production of transplant seedlings; through a suitable acid
soils planted Hook, provide sufficient moisture, light conditions
and fertilizers, etc., to create the right triptolide external
conditions; through defloration after planting and field
management practices such as topping promote triptolide medicinal
parts of the underground part of the growth of transplanted 2-4 in
Hook after years of medicinal use as a raw material.  
  
 **Specific embodiments**Chinese medicine Tripterygium planting method
comprises the following steps:  
  
1. Cutting propagation (a) cuttings ready to collect 1 to 2 years
old, robust, no pests branches, cut into 10 ~ 15cm long cuttings,
each with three to four sections.  
  
Will be tied into bundles by cuttings or root excavation three
years triptolide, clipping diameter 0.2 ~ 4cm, length 10 ~ 15cm
intact root segments and set aside. (  
  
2) cutting method in late January to mid-March or late September
to mid-October, will be ready cuttings (root without reagent) into
the lower end 500 ~ 1000ppm of a-NAA or IBA solution immersed,
remove a little dry ie the spacing of 10cm x 10cm Xiecha on
prepared seedbed, buried 1/2 to 2/3.  
  
Inserted immediately after watering, to build approximately 50cm
high Shed, cover film, surrounded by soil compaction, such as the
sun is strong, the need to cover shade net.  
  
About 40 ~ 50d, after rooting, thrown off film and shade net.  
Kind of root without pre-treatment, the other with cuttings.  
  
2. Colonization (1) in the year in November to next March
planting, 80cm in width planted on the plot line, spacing 60 ~
90cm, with a volume of 800 to 1000 seedlings / acre. (2) on the
open furrow at planting at 60 ~ 90cm x 60 ~ 90cm of the planting
hole depth of about 40 ~ 50cm, planted a per hole, planting
seedlings roots will start righting seedlings, while gently
lifting the edge of the casing seedlings, casing to cover no
roots, compacted.   
  
(3) Each fertilizing before planting organic fertilizer products
100 ~ 300g, ash 200 ~ 400g, rapeseed fat 15 ~ 45g.  
Cast basal fertilizer, seedling roots and then to high overburden
portion 5cm, compaction, irrigated.  
  
3. Fertilizer every spring sprouted new little after mid-May on,
combined with weeding, applying chemical fertilizer (potassium
chloride type) in plants around the root, 15 ~ 20kg / acre.  
In July and August, the election evening or cloudy, spraying 0.3%
potassium dihydrogen phosphate, 50kg / acre.  
  
In October and November, the plant four weeks at 20 ~ 30cm ring
ditch, applied into organic fertilizer products, 400 ~ 600kg /
acre.  
  
4. Field management (1) in the June to August Hook flowering,
election sunny, timely removal of buds, check once every 10d. (  
2) In May to September, the election sunny, slightly longer in the
new time to 40 ~ 60cm, cut off or removal of the terminal bud,
check once every 20d.  
  
5. Cuttings after transplanting, biennial Tripterygium wilfordii
mu fresh herbs Weight 800-1000kg, three students Tripterygium
wilfordii mu fresh herbs Weight 2500-3000kg.  
  
**Example 1**  
1. Tripterygium cultivation of traditional Chinese medicine,
characterized in that it comprises the steps of:  
  
1) cuttage  
  
(A) collecting a year old, robust, no pests branches, cut into
10cm long cuttings, each with three sections, cuttings will be
tied into bundles, or takes more than 3 years triptolide kind
roots, clipping diameter 0.2cm, length 10cm seed roots, spare;  
  
(2) into the bottom of the prepared cuttings 500ppm of a-NAA or
IBA solution immersed, remove a little dry Xiecha the prepared
seedbed, or on the prepared kind of root segments oblique inserted
in a prepared seedbed, buried 1/2, inserted immediately after
watering, cover film, surrounded by soil compaction;  
  
2) colonization  
  
(A) in the year in November to next March planting, spacing 60cm,
with a volume of 1400 seedlings / acre, planted in well-drained
slightly acidic pH 5 red loam or silt soil type;  
  
(2) on the open furrow at planting in the planting hole 60cm x
60cm, depth 40cm, planted one per hole, planting seedlings root
system will start righting seedlings, while gently lifting the
edge of the casing seedlings, soil to cover no roots, compaction;  
  
(3) fertilizing before planting organic fertilizer products per
100g, ash 200g, rapeseed fat 15g.  
  
Cast basal fertilizer, seedling roots and then to high overburden
portion 5cm, compaction, irrigated;  
  
3) fertilization  
  
In the spring of each year after birth, a new little pumping,
combined with weeding, applying fertilizer on potassium
chloride-based chemical plants around the root, 15kg / acre, in
July and August, the election evening or cloudy, spraying 0.3%
potassium dihydrogen phosphate , 50kg / acre, in October and
November, the plant four weeks of 20cm ring ditch, applied into
organic fertilizer products, 400kg / acre;  
  
4) field management  
  
(A) in the June to August Hook flowering, election sunny, timely
removal of buds, check once every 10d;  
  
(2) in May to September, the election sunny day, when the new
little longer to 40cm, pruning or removal of the terminal bud,
check once every 20d;  
  
5) cuttings after transplanting, harvesting two to three years.  
Implementation of the results: the average two-year old plants per
plant weight 0.557kg, converted into yield as 779kg.  
  
**Example 2**  
1. Tripterygium cultivation of traditional Chinese medicine,
characterized in that it comprises the steps of:  
  
1) cuttage  
  
(A) Acquisition 2 years old, robust, no pests branches, cut into
15cm long cuttings, each with four sections, the cuttings tied
into bundles, or takes more than 3 years triptolide kind roots,
clipping diameter 4cm, length 15cm seed roots, spare;  
  
(2) into the bottom of the prepared cuttings 1000ppm of a-NAA or
IBA solution immersed, remove a little dry Xiecha the prepared
seedbed, or on the prepared kind of root segments oblique inserted
in a prepared seedbed, buried 2/3, inserted immediately after
watering, cover film, surrounded by soil compaction;  
  
2) colonization  
  
(A) in the year in November to next March planting, spacing 90cm,
with a volume of 822 seedlings / acre, planted in well-drained
slightly acidic pH of 6 red loam or silt soil type;  
  
(2) on the open furrow at planting in the planting hole 90cm x
90cm, depth 50cm, planted one per hole, planting seedlings root
system will start righting seedlings, while gently lifting the
edge of the casing seedlings, soil to cover no roots, compaction;  
  
(3) fertilizing before planting organic fertilizer products per
300g, ash 400g, rapeseed fat 45g.  
  
Cast basal fertilizer, seedling roots and then to high overburden
portion 5cm, compaction, irrigated;  
  
3) fertilization  
  
In the spring of each year after birth, a new little pumping,
combined with weeding, applying fertilizer on potassium
chloride-based chemical plants around the root, 20kg / acre, in
July and August, the election evening or cloudy, spraying 0.3%
potassium dihydrogen phosphate , 50kg / acre, in October and
November, the plant four weeks at 30cm ring ditch, applied into
organic fertilizer products, 600kg / acre;  
  
4) field management  
  
(A) in the June to August Hook flowering, election sunny, timely
removal of buds, check once every 10d;  
  
(2) in May to September, the election sunny day, when the new
little longer to 60cm, pruning or removal of the terminal bud,
check once every 20d;  
  
5) cuttings after transplanting, harvesting two to three years.  
Implementation of the results: the average two-year old plants per
plant weight 1.26kg, was converted into yield 1057kg.  
  
**Example 3**  
1) cuttage  
  
(A) Acquisition 2 years old, robust, no pests branches, cut into
12cm long cuttings, each with four sections, the cuttings tied
into bundles, or takes more than 3 years triptolide kind roots,
clipping diameter 2cm, length 12cm seed roots, spare;  
  
(2) into the bottom of the prepared cuttings 800ppm of a-NAA or
IBA solution immersed, remove a little dry Xiecha the prepared
seedbed, or on the prepared kind of root segments oblique inserted
in a prepared seedbed, buried 1/2, inserted immediately after
watering, cover film, surrounded by soil compaction;  
  
2) colonization  
  
(A) in the year in November to next March planting, spacing 80cm,
with a volume of 1040 seedlings / acre, planted in well-drained
slightly acidic pH of 6 red loam or silt soil type;  
  
(2) on the open furrow at planting in the planting hole 80cm x
80cm, depth 450cm, planted one per hole, planting seedlings root
system will start righting seedlings, while gently lifting the
edge of the casing seedlings, soil to cover no roots, compaction;  
  
(3) fertilizing before planting organic fertilizer products per
200g, ash 300g, rapeseed fat 40g.  
  
Cast basal fertilizer, seedling roots and then to high overburden
portion 5cm, compaction, irrigated;  
  
3) fertilization  
  
In the spring of each year after birth, a new little pumping,
combined with weeding, applying fertilizer on potassium
chloride-based chemical plants around the root, 18kg / acre, in
July and August, the election evening or cloudy, spraying 0.3%
potassium dihydrogen phosphate , 50kg / acre, in October and
November, at the plant four weeks 25cm ring ditch, applied into
organic fertilizer products, 500kg / acre;  
  
4) field management  
  
(A) in the June to August Hook flowering, election sunny, timely
removal of buds, check once every 10d;  
  
(2) in May to September, the election sunny day, when the new
little longer to 50cm, pruning or removal of the terminal bud,
check once every 20d;  
  
5) cuttings after transplanting, harvesting two to three years.  
Implementation of the results: the average two-year old plants per
plant weight 0.824kg, converted into yield as 856kg.  
  
**1 Materials and methods****1.1 Material Selection**  
1.1.1 cuttage year students selected semi-woody cuttings of
branches, removal of woody base and not the top choice among
strong position, cut into about 8 ~ 10cm, there are three to four
buds pieces, and cut leaves go half cuttings with different
concentrations of IBA, NAA speed dip method was used for
processing, processing method: Cuttings were fast speed in the
solution dipped about 5s (depth of about 3cm), immediately
cutting.  
  
Each treatment selection cuttings 50.  
  
On the whole a good seedbed by spaced 1.2cm ridging, furrow
between 30cm wide ditch dug, Goushen 20 ~ 25cm, 20cm x 20cm
spacing will press cuttings inserted in the furrow, the cuttings
into the soil deep 3 ~ 5cm .  
  
Irrigated immediately after cutting and covering shade net, in
order to maintain proper temperature and humidity.  
  
Previous regular watering, keep moist, observe the hair root
cuttings survival situation.  
  
1.1.2 set five kinds of planting density (cm x cm); 40 x 40,50 x
50,60 x 60,80 x 80 and 100 x 100 and other five, randomized block
arrangement, a total of three replicates.  
  
Each treatment plot size of 5 x 24 = 120m2.  
  
Each treatment on November planting seedlings, planting, the
seedlings are basically the same size, in addition to density, the
other management measures with the general field.  
  
1.1.3 Fertilization  
  
1.1.3.1 Hook N, P, K inorganic fertilizer test Test for using
annual cuttings and seedlings, planting seedlings when fresh
weight per clump 42.5g.  
  
Test soil loam March 14 planting density of 50cm x 50cm.  
March 15 basal application, June 17 dressing application.  
Trial randomized block design as shown in Table 1, three times
repeated, residential area of ??0.02 acres.  
Test basal and top dressing fertilizer distribution ratio shown in
  
Table 2.  
  
Table 1 TWH NPK fertilizer fertilization designed to handle the
table  
  
Table 2 Hook Test fertilizer allocation table  
  
1.1.3.2 Hook organic manure fertilization experiment set low,
medium, and high levels of fertilizer, is a random permutation
block design with three replicates were set.  
  
Residential area of ??5m x 24m = 120m2, planting 480, Qikuan to
1.2m, kind of two rows, spacing of 50cm x 50cm.  
  
Planting time for the year in November.  
  
Seed selection of local wild species breeding cuttings annual
seedlings, basically the same size specifications.  
  
Basal all use organic fertilizer was applied in one hole when
planting, each pit into the standard as shown in Table 3.  
  
Table 3 Fertilization Fertilization planting hole standard units:
g / hole  
  
3 times a year for dressing: 1st time in late March - late April,
in the same furrow between two rows of Summer into the open,
fertilization criteria in Table 4.  
  
2 inferior August to September, select cloudy or 16:00 after the
foliage top dressing, spray 0.3% potassium dihydrogen phosphate,
according to low, medium and high levels, respectively, spray one,
two, three times.  
  
3 inferior to 10 months late, the same method was applied to the
1st, fertilization criteria in Table 5.  
  
Table 4 1st top dressing fertilizer standard unit: g  
  
Table 5 3rd top dressing fertilizer standard unit: g  
  
1.1.5 Hook herbs growth cycle relationship with yield trials using
annual Hook cuttings, planting spacing of 80cm x 80cm, planted in
November that year, planted on the plot line, with the amount of
800 to 1000 seedlings / acre.  
  
Respectively, in the second year, third year, fourth year in
November harvest roots, fresh herbs yield determination.  
  
**1.2 Results and Analysis****1.2.1 Growth Regulators speed dip method**  
Table 6 Growth Regulators cutting speed dip process results  
  
Been observed, the use of growth regulators, can promote early
hair roots, early bud and root vigor strong and well developed.  
Do not use the hair root growth regulators and late survival rate
is low, the use of growth regulators to 500ppm of IBA or NAA speed
dip method is better.  
  
Tripterygium cutting tests carried out hormone treatment were used
1000ppm, 500ppm, 100ppm Chennai acetic acid (NAA), carried out
immediately after cutting and quick dip before placing 30min
cuttings, cuttings clipped from the Health and semi-woody
branches, cuttings spacing of 10cm x 10cm, and irrigated, covered
with shade net.  
  
The results are shown in Table 7.  
  
Table 7 Growth Regulator cuttings result of different treatment  
  
Through years of cuttings experimental observation, the use of 500
~ 1000ppm of IBA or NAA, using quick dip or soak immediately after
cutting, help to improve the survival rate of cuttings and promote
early root; root cuttings root than stem cuttings root system, but
Stem cuttings relatively low cost, easy to breed a large area.
Stem cuttings used in conjunction with film and shade net, can
significantly improve the survival rate.  
  
In the cutting time, the root cuttings for 2 to 3 months is
appropriate, while stem cuttings should choose nine to 10 months
or for the rainy season in June.  
  
Cuttings should use when students lignified.  
  
1.2.2 planting density test results  
  
Table 8 Hook density test yields results  
  
Table 9 density test analysis of variance table  
  
As can be seen from Table 8, as the density decreases more and
more important roots of Tripterygium, process 5 to process 96% of
weight 1; and the root length and longer, the process 5 58% longer
than the process 1.  
  
According to analysis of variance table, yield differences between
treatments was significant.  
  
From the root distribution, root distribution deal with
high-density range is small, and low density and wide
distribution.  
  
But the handling and processing 4 5 several other differences were
not significantly different, indicating that process 5 to process
4 is not particularly significant differences.  
  
Hook for the deep roots of plants to root medicine, but also on
the ground Fujimoto relatively long, so when planting triptolide,
density should be smaller, not too dense.  
  
Generally 80cm x 80cm fit, too dense, plant growth is relatively
small, and poor root growth, density is too large, the root weight
gain is not obvious.  
  
Deep plowing before transplanting planting ground at 40 ~ 50cm,
flat, made of 80cm wide furrows, planting a row, so that
triptolide growth than the open furrow kind of two rows of 120cm
better.  
  
1.2.3 Fertilization results  
  
1.2.3.1 N, P, K inorganic fertilizer trials  
  
January 7 next year, each plot were randomly digging five Cong
said the fresh weight, are shown in Table 10.  
  
Table 10 TWH fertilizer production acceptance test table (5 Cong)
Unit: kg  
  
Table 11 plot yield analysis of variance table  
  
According to test results, the five cluster production to deal
with 9 being the highest, compared with the minimum production
processing a high of 135%.  
  
Yield based on 5 Cong variance analysis showed that the treatments
  
yield reached a very significant level, and area difference
between the groups was not significant.  
  
According to the results, the application of potassium fertilizer
on yield triptolide has a great impact, and phosphate fertilizer
production although triptolide have a certain impact, but the
impact is not big potash.  
  
Therefore, more should be applied in the production of potash, and
phosphate may be appropriate to impose a number.  
  
1.2.3.2 organic fertilizer test results are shown in Table 12  
Table 12 TWH fertilization experiment unit of production: kg/m2  
Table 13 plot yield fertilization experiment analysis of variance
table  
According to the test results, the cell production to the highest
level, compared with the high level of 23.4%, compared with 58.3%
in low-level high.  
  
According plot yield variance analysis showed that the treatment
cell production reached a significant level.  
  
From the root morphology of view, a high level of the most
developed root system, white fibrous roots is also up; horizontal
roots are more developed, but the white be no more than a high
level; low roots not only short, but also less fibrous roots.  
  
Thus, the public rattan cane crop is like fertilizer, fertilizer
helps triptolide more root development, because the roots for
medicinal triptolide, so should be more pre tripterygium
fertilization.  
1.2.4 The relationship between yield and growth cycle triptolide  
Hook annual cuttings after transplantation, planting fresh herbs
yield of two years 800 ~ 1000kg, three students fresh herbs yield
of 2000 ~ 2600kg, four students per mu yield of 2120 ~ 2750kg.  
  
Visible, triptolide born four years compared to three students in
terms of yield, yield increase is not much, considering the
economic and herbs yield two factors, the production of three
students to harvest herbs as raw materials.  
  


---

  

**Tripterygium wilfordii diterpene
lactone compounds for curing cancer**  
**CN101273986**

  
The invention discloses a method for using a diterpene lactone
compound of tripterygium in the treatment of cancers. The
diterpene lactone compound comprises diterpene lactone alcohol of
tripterygium, diterpene lactone glycol of tripterygium, diterpene
lactone ketone of tripterygium and a plurality of derivatives of
the diterpene lactone alcohol of tripterygium.  
  


---

  

**Preparation method of culture composts
for growing tarragon**  
**CN101624318**

  
The present invention discloses a method which utilizes the
Tripterygium wilfordii cell culturing method to produce triptolide
and Tripterygium wilfordii alkaloid. The method utilizes
adventitious roots formed by the annual stuck branches of
Tripterygium wilfordii as raw material to conduct callus induction
and subculture on explants, establish suspension cell lines and
establish and screen out cell suspension systems which can
suitably utilize the two-step cell culturing method to produce the
triptolide and the alkaloid, and corresponding growth culture
media and formulae of producing a triptolide culture medium and a
Tripterygium wilfordii alkaloid culture medium thereof.; The
method, which is utilized to produce the triptolide and total
alkaloids from Tripterygium wilfordii, is characterized by short
production cycle, high efficiency, environment-friendliness, etc.
and helps to protect the natural Tripterygium wilfordii resource.  
  


---

  

**Attenuation method of tripterygium
wilfordii**  
**CN101361779**

  
The invention discloses a method for the attenuation of
tripterygium wilfordii. The original powder of the tripterygium
wilfordii is evenly mixed with wheat bran and soybean flour;
fermentations obtained from the common pile fermentation of Pu-erh
tea within the fourth to tenth day or hair mould or aspergillus
fumigatus is taken as inoculums; the mixed material is added with
boiled water to sterilize for 40min to 120min by steam and cooled
to 35 DEG C, after that, the mould or the fermentations is
inoculated, then purified water is added, culturing is carried out
for 4 days to 10 days under the condition with temperature of 25
DEG C to 40 DEG C and relative humidity of 50 percent to 80
percent, the ethanol is recycled by ethanol-extracting, and an
extract for the attenuation of tripterygium wilfordii is obtained
after concentration and desiccation are carried out.; The
invention utilizes the integral translation effect of
microorganisms, not only realizes the goal of toxicity reduction,
but also has the effect of enhancing pharmacological activity. As
raw medicinal materials that are not extracted and separated are
directly adopted, products of translation can be directly prepared
into a proper dosage form used for clinical treatment, thereby
avoiding resource waste caused by translating substances with
single activity and being beneficial to the full utilization and
sustainable development of tripterygium wilfordii biotic
resources.  
  


---

  

**Tripterygium wilfordii Hook.f total
terpenoid vesicles and preparation method**  
**CN101797278**

  
The invention discloses Tripterygium wilfordii Hook.f total
terpenoid vesicles and a preparation method thereof and a
preparation containing the Tripterygium wilfordii Hook.f total
terpenoid vesicles and a preparation method thereof, and belong to
the field of medicaments. The Tripterygium wilfordii Hook.f total
terpenoid vesicles are prepared from Tripterygium wilfordii Hook.f
total terpenoid, a non-ionic surfactant, cholesterol and an
additive. The Tripterygium wilfordii Hook.f total terpenoid
vesicles is preferably prepared into an external gel formulation.
The external percutaneous-administration preparation of the
Tripterygium wilfordii Hook.f total terpenoid has unique
advantages; a novel vesicle administration system is used to
increase the percutaneous absorption of the medicament, strengthen
the clinical effects and avoid the side or toxic effect during
oral administration or injection administration; and the external
percutaneous-administration preparation has the treatment effects
of preventing inflammation, relieving pain and the like and can be
used for treating rheumatoid arthritis and the like.  
      


---

  

**Method for tissue culture and rapid
propagation of medicinal herb tripterygium wilfordii**  
**CN102090334**

  
The invention provides a method for tissue culture and rapid
propagation of a medicinal herb tripterygium wilfordii medicinal
material. The method comprises the following steps: preparing an
explant; performing primary culture; performing propagation
culture; hardening-off; performing rooting culture; and
transplanting tissue culture seedlings. On the theoretical basis
for screening good clones and determining a scientific induction
technology, through clone variation, mutagenesis, chromosome
doubling, suspended cell culture, filial generation acclimation
screening and other means to the optimized tripterygium wilfordii
provenance, the method provided by the invention can be used for
realizing cultivation of good regenerated tripterygium wilfordii
plants, and constructing a tripterygium wilfordii superior variety
tissue culture base.  
  


---

  

**Tripterygium wilfordii hook
acclimatization and high-yielding method****CN102106231**

  
The invention provides a tripterygium wilfordii hook
acclimatization and high-yielding method. A cut section of the
stem of the tripterygium wilfordii hook is adopted for culturing
and breeding, and abundant materials provide a foundation for
breeding and acclimatization of mass wild tripterygium wilfordii
hook. The method comprises the following steps: preparing a
nursery garden; raising seedlings by cutting; transplanting; and
managing a base. The method is a complement for wild tripterygium
wilfordii hook resources, and has great significance in developing
subsequent industry of tripterygium wilfordii hook
exploitation.      
  


---

      

**METHODS OF FREEZE-DRYING AND
DEBARKING THE ROOTS OF A T. WILFORDII HOOK F. PLANT  
 AND METHODS OF PROCESSING EXTRACTS****WO2012154717**

  
**FIELD OF THE INVENTION**

[0001] The disclosed subject matter generally relates to plants
and plant products and more specifically relates to Tripterygium
wilfordii Hook F. plants, plant products and methods of making and
using extracts of such plants and plant products.  
  
**BACKGROUND OF THE INVENTION**  
[0002] Tripterygium wilfordii Hook F. (TwHF) (Celastraceae),
commonly known as Thunder god vine, is a perennial shrub
indigenous to China and Southeast Asia. TwHF contains a number of
chemical compounds that are toxic. Parts of the TwHF plant, such
as the leaves, the stem, flowers, and the skin and/or bark of the
roots are poisonous and may cause death if ingested. TwHF has been
used in traditional Chinese medicine to treat diseases and
disorders, but the uses are limited by the significant toxicity
risk. Administration of TwHF has also been shown to inhibit
interleukin-2-mediated immunosuppression.  
  
Administration of a TwHF extract or its components, {e.g.,
triptolide and tripdiolide, compounds obtained from TwHF), has
been shown to inhibit interleukin-2 (IL-2).  
  
Purification of such compounds is costly and time-consuming, but
necessary in view of the toxins. Use of less purified materials
from the plant presents the risk that the benefits of therapy will
be outweighed by the risks of deleterious consequences resulting
from administration of toxic substances.  
  
[0003] The inflammatory response is associated with invasion of a
body by a foreign object or injury. On occasion, inflammatory
responses, both acute and chronic, develop under circumstances
where the body is not under true threat, and the inflammatory
response itself becomes a condition or disorder requiring
treatment. Analogously and closely aligned, the immune response
wards off invasion by foreign objects, but that response also
occurs under inappropriate circumstances, such as when there is no
foreign object. A variety of disorders are characterized by
inappropriate immune responses, exemplified by the various
auto-immune disorders known to man. A continuing effort is being
made to provide more effective and safer treatments for disorders
involving inappropriate immune responses and/or inappropriate
inflammatory responses.  
  
[0004] For the foregoing reasons, a need continues to exist in the
art for compositions comprising the beneficial biologically active
compounds of TwHF with an acceptably reduced presence of TwHF
toxins, that are useful in preventing, mitigating, treating or
ameliorating a symptom of an inappropriate inflammatory response
and/or an inappropriate immune response.  
  
**SUMMARY OF THE INVENTION**  
[0005] Described herein are methods for obtaining and processing
extracts of the Tripterygium wilfordii Hook F. (TwHF) plant that
provide beneficial biologically active compounds with an
acceptably reduced level of toxic substances that improves the
safety profile. The methods yield natural products that provide
the benefits of TwHF without undue risk of harming recipients that
characterizes use of the native plant...  
  
**DETAILED DESCRIPTION OF THE INVENTION**  
  
[0066] The present application is based on the discovery that
freeze-drying the roots of a TwHF plant facilitates comprehensive
removal of the bark from the root core, which allows for the
preparation of extracts that substantially lack the toxic
compounds (e.g., celastrol) present in the bark.  
  
[0067] The present application is also based on the discovery that
non-polar organic solvents and formulation excipients are capable
of transforming conventional extracts of a TwHF plant into a
freely flowable solid. Conventional extracts of a TwHF plant
produced by methods known in the art (e.g., solids isolated from
alcoholic extractions of a TwHF plant without any further
processing steps) are waxy, amorphous solids (i.e., a native
extract) with poor flow characteristics that require extraordinary
means to manipulate and produce a useable drug product. The freely
flowable solids produced by the processing methods described
herein contain useful levels of extract compounds (e.g.,
triptolide and tripdiolide), and these extract compounds can be
formulated into a drug product for the treatment of various
disorders, including anti-inflammatory disorders such as
rheumatoid arthritis.  
**II. Methods of Freeze-Drying Roots of the TwHF plant.**  
  
[0076] As demonstrated in the Examples provided herein,
freeze-drying the roots or root portions of a TwHF plant prior to
removing the bark allows for easy, quantitative removal of the
bark compared to conventional methods. Freeze-drying is a
dehydration process in which water is removed from the root of a
TwHF plant without exposing the plant material to protracted
periods of exposure to the potentially deleterious effects of
liquid water and/or excessive heat. The freeze-drying process can
be performed with any method known in the art as well as in any
freeze-drying apparatus known in the art.  
  
[0077] One aspect of the disclosure provides a method of producing
freeze-dried root portions from the roots of a TwHF plant, wherein
the method comprises placing a plurality of frozen root portions
in a container within a freeze-drying chamber, wherein the roots
are sufficiently close in proximity to each other within the
container to facilitate heat transfer; lowering the pressure
within the chamber; and heating the container by an amount
sufficient to sublimate the water in the root portions, thereby
producing freeze-dried root portions of a TwHF plant.  
  
[0078] The first step of the freeze-drying process is the freezing
of the root portions. The roots of the TwHF plant can grow to a
length of up to 12 meters, which is too large to fit into most
commercial freeze-drying chambers. Thus, in some embodiments, it
is desirable to process or mill the roots of the TwHF plant prior
to beginning the freeze-drying process in order to produce root
portions of a more manageable size. The TwHF roots are processed
to a desired length or range of lengths before or after freezing,
but prior to freeze-drying. For example, in some embodiments, the
roots of the TwHF plant are processed to produce root portions of
a length of about 24 inches or less. In some embodiments, the
roots of the TwHF plant are processed to produce root portions of
a length of about 12 inches, about 11 inches, about 10 inches,
about 9 inches, about 8 inches, about 7 inches, about 5 inches,
about 4 inches, about 3 inches, about 2 inches, about 1 inch,
about [1/2] inch, or less. In some embodiments, the roots of the
TwHF plant are processed to produce root portions of a length of
about 6 inches.  
  
[0079] In some embodiments, a root of the TwHF plant has a
diameter of about [1/2] inch or less. In some embodiments, a root
has a diameter of about 1/3 inch, [1/4] inch, 1/8 inch, 1/16 inch
or less. In other embodiments, a root of the TwHF plant has a
diameter of about 1 inch or more. In one embodiment, the roots of
the TwHF plant are processed to produce root portions of a length
of about 6 inches and a diameter of about [1/2] inch. Typically,
TwHF roots are not processed to alter the average diameter
thereof, but the disclosure contemplates such processing using any
conventional milling technique where reduced diameters and
increased surface are desired (or at least not undesired) to more
efficiently freeze-dry the preparation. Given that the roots or
root portions are subject to extraction, various lengths and
diameters of roots and root portions are acceptable, including
ground, macerated or pulverized roots and root portions.  
  
[0082] Root portions are obtained from a TwHF plant of any age. In
some embodiments, the root portions are obtained from a TwHF plant
that is grown for less than about 30 months. In related
embodiments, the root portions are obtained from a TwHF plant that
is cultivated for about 29 months, 28 months, 27 months, 26
months, 25 months, 24 months, 23 months, 22 months, 21 months, 20
months, 19 months, 18 months, 17 months, 16 months, 15 months, 14
months 13 months, 12 months, 11 months, 10 months, 9 months, 8
months, 6 months or less. In other embodiments, the root portions
are obtained from a TwHF plant that is grown for at least 30
months or longer. In such embodiments, the root portions are
obtained from a TwHF plant that is cultivated for about 31 months,
32 months, 33 months, 34, months, 35 months, 36 months, 37 months,
38 months, 39 months, 40 months, 41 months, 42 months, 43 months,
44 months, 45 months, 46 months, 47 months, 2 years, 3 years, 4
years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years or
more...  
  
[0083] A variety of approaches are suitable for freezing the TwHF
roots or root portions from which extracts are to be prepared. In
some embodiments, the freezing process is performed by placing the
root portions in a container and placing the container in a
dedicated freezing apparatus (i.e., a freezing apparatus that is
separate from the freeze-drying chamber) overnight prior to
beginning the freeze-drying process. The root portions are placed
sufficiently close to each other within the container to
facilitate heat transfer during the freeze-drying process.
Preferably a root portion is in contact with at least one other
root portion and/or with the container to facilitate heat transfer
by conduction. The container may be composed of any material or
materials, preferably conductive material(s). The container is of
any shape or footprint compatible with the freeze-drying chamber.
The container is any depth compatible with the internal dimensions
of the freeze-drying chamber; in some embodiments, the container
has a depth of no more than 2 inches, such as a depth in the range
of 0.125-2.0 inches, or a nominal height. In some embodiments, the
root portion is cooled below its eutectic point to ensure the
absence of liquid-phase material, regardless of the pressure.  
  
[0084] The use of any commercial freezing apparatus (e.g.,
freezer) that is capable of reducing the temperature of the root
portions to a temperature ranging from -10[deg.]C to -70[deg.]C is
specifically contemplated. In some embodiments, the temperature of
the root portions is reduced to a temperature ranging from
-20[deg.]C to about -70[deg.]C. In some embodiments, the
temperature of the root portions is reduced to a temperature of
about -20[deg.]C, -25[deg.]C, -30[deg.]C, -35[deg.]C, -40[deg.]C,
-45[deg.]C, -50[deg.]C, -55[deg.]C, -60[deg.]C, -65[deg.]C or
about -70[deg.]C. In some embodiments, the temperature of the root
portions is reduced to a temperature of about -20[deg.]C. Once the
roots have been frozen at the desired temperature, the container
comprising the frozen root portions is placed in a freeze-drying
chamber, the temperature of which is maintained at a temperature
of about -20[deg.]C or lower...  
  
[0086] Once the freeze-drying chamber has reached the desired
temperature and the root portions have been placed in the
freeze-drying chamber, the pressure in the chamber is lowered in
order for water within the root portions to sublimate. In some
embodiments, heat is applied to the root portions to facilitate
removal of water from the root portions. During this process, at
least 50% of the water in the root portions is sublimated. In some
embodiments, at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%,
95%, 96%, 97%, 98%, 99% or more of the water in the root portions
is sublimated. In some embodiments, heat is applied to the root
portions indirectly by incrementally increasing the temperature of
the freeze-drying chamber from about 10[deg.]C to about 70[deg.]C.
In some embodiments, the temperature of the chamber is first
increased to about 10[deg.]C and the temperature is stabilized at
about 10[deg.]C overnight. The temperature of the chamber is then
increased to about 35[deg.]C for about 8 hours and then increased
to about 50[deg.]C for about 8 hours. At the end of the freeze-
drying process, the final residual water content in the
freeze-dried root portions is, in some embodiments, about 20% or
lower. In some embodiments, the freeze-dried root portions contain
no more than 15% water. In other embodiments, the freeze-dried
root portions contain no more than 10% water. In other
embodiments, the freeze-dried root portions contain no more than
5% water or less. In other embodiments, the freeze-dried root
portions contain no more than 2% water or less.  
  
[0087] The pressure of the freeze-drying chamber is controlled
through the application of a vacuum. The vacuum is employed to
facilitate sublimation. In some embodiments, the pressure within
the freeze-drying chamber ranges from about 3 to about 10
millibar. In some embodiments, the pressure within the
freeze-drying chamber is no more than 0.01 atm.   
  
[0088] A cold condenser chamber and/or a condenser plate is/are
used, in some embodiments, to provide a surface upon which water
vapor may be contained and/or collected. By utilizing a condenser,
water vapor is prevented from reaching the vacuum pump, which
could degrade the performance of the pump. The condenser is
maintained at a temperature known in the art as useful in
de-humidification. In some embodiments, the temperature of the
condenser is maintained at -50[deg.]C or lower. In some
embodiments, the temperature of the condenser is maintained at
-30[deg.]C or lower.  
  
[0089] The resulting freeze-dried root portion of the TwHF plant
comprises a root core and bark, wherein the attachment of the bark
to the root core is altered, thereby reducing the strength of
attachment of the bark to the root core relative to a fresh TwHF
root portion of comparable dimensions. Without wishing to be bound
to any particular theory, it is contemplated that a thoroughly
dried root portion of a TwHF plant prepared, for example,
according to a freeze-drying method described herein, allows for
more quantitative removal of bark from the root core. Extracts
obtained from such freeze-dried debarked root cores are expected
to contain considerably lower levels of toxic compounds (e.g.,
celastrol) compared to extracts obtained from root cores in which
the bark has been removed by conventional methods without first
being freeze-dried or obtained from root cores that are
freeze-dried, but wherein the freeze-drying process did not result
in substantial sublimation of the water within the root portions.  
  
**[0090] III. Methods of Debarking the Roots of the TwHF Plant**  
[0096] Compounds present in the bark of a TwHF plant can be used
as markers to determine whether a measurable amount of bark is
present on the freeze-dried debarked root portions. Celastrol is a
triterpenoid antioxidant compound present in the bark a TwHF
plant. Thus, in some embodiments, a method of identifying residual
bark in a preparation of freeze- dried debarked root portions of a
TwHF plant comprises determining the amount of a bark marker
{e.g., celastrol) in the preparation of freeze-dried debarked root
portions, wherein lower amounts of the marker in the preparation
of freeze-dried debarked root portions identifies the preparation
as containing lower amounts of residual bark. The amount of
celastrol in the freeze-dried root portions can be determined by
methods known in the art, such as NMR or HPLC. [0097] In some
embodiments, the freeze-dried debarked root portions comprise less
than 10% celastrol compared to the amount of celastrol present in
bark of comparably dimensioned fresh root portions of a TwHF
plant. In some embodiments, the freeze-dried debarked root
portions comprise less than 5%, 4%, 3%, 2%, 1%, or less celastrol
compared to the amount of celastrol present in bark of comparably
dimensioned fresh roots of a TwHF plant.  
  
**IV. Methods of producing an extract of a TwHF plant**  
[0098] Methods of producing an extract from the roots of a TwHF
plant are known in the art. Conventional extraction methods
comprise grinding, milling or pulverizing plant material (e.g.,
debarked roots of a TwHF plant); extracting the plant material in
a solution containing a sufficient amount of extractant fluid
(e.g., an alcohol); and collecting the fluid to obtain an extract
mixture (e.g., an alcoholic extract). The extract mixture may be
further processed by removing solid matter from the extract
mixture. Solid matter is removed from the extract by any method
known in the art including, but not limited to, filtration and
centrifugation. In some embodiments, the roots or root portions of
the TwHF plant are debarked using the freeze-drying and debarking
methods described herein. In other embodiments, the roots or root
portions of the TwHF plant are fresh roots or portions that have
been debarked using methods known in the art.  
  
[0099] Grinding, milling or pulverizing debarked roots of a TwHF
plant can be performed by any conventional milling process to
increase the surface area of the root cores exposed to an
extractant fluid.  
  
[00100] In some embodiments, the extractant fluid for use in the
extraction method is a solvent. Suitable extractant fluids
include, but are not limited to, water, alcohols, aqueous
solutions, halocarbons, esters and supercritical fluids. Suitable
alcohols include primary alcohols such as ethanol, N-propanol,
N-butanol, N-pentanol, N-hexanol, N-octanol, N- nonanol and
N-decanol as well as secondary alcohols such as isopropanol,
isobutanol, and the secondary alcohol derivatives of, e.g., any of
butane through decane. For those lower molecular weight compounds
that are gases at room temperature and about one Atm, pressurized
extractions in which the compounds are in a liquid state are
contemplated. In one embodiment, the extractant fluid is ethanol.
A benefit of incorporating an ethanolic fluid during the
extraction process is that an ethanolic fluid is compatible with
an ingestible product, and therefore is suitable for use in
preparing an extract for incorporation into a pill, capsule,
tablet, and other ingestible forms known in the art.  
  
[00101] In one aspect, the extracting step comprises combining
debarked roots, milled if desired, with an excess of extractant
fluid such as 2- to 20-volumes of extractant fluid per unit volume
of milled roots, and the combined materials are stirred for a time
sufficient to extract the compounds of interest from the milled
roots. In some embodiments, the mixture comprising the extractant
fluid and the milled roots is stirred for about 30 minutes, 1
hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8
hours, 9 hours, 10 hours or longer.  
  
Optionally, the mixture is stirred at reflux. The extraction
process is conducted at a temperature of between room temperature
and the boiling point of the extractant fluid.  
  
[00102] In some embodiments, the mixture is filtered and the
filtrate is concentrated until the concentrated filtrate is a
fraction of the volume of the initial filtrate. In some
embodiments, the concentrated filtrate is less than 1, 0.9, 0.8,
0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1 or fewer volumes relative to the
initial filtrate. In some embodiments, the roots, milled if
desired, are subjected to a series of extractions with the
extractant fluid. In such embodiments, the roots are again
combined with an excess of extractant fluid and the extraction
process is repeated. The filtrates obtained from the various
extractions are then combined and concentrated as described below.  
  
[00103] Concentration of the filtrate(s) is accomplished by
methods known in the art, such as through the use of a vacuum to
remove a volatile fluid, e.g. , solvent. The concentration of the
filtrate occurs at any temperature. In some embodiments, the
temperature does not exceed 50[deg.]C. Concentrating the filtrate
at a temperature of about 20[deg.]C, 25[deg.]C, 30[deg.]C,
35[deg.]C, 40[deg.]C, 45[deg.]C, 55[deg.]C, 60[deg.]C, 65[deg.]C,
or 70[deg.]C is also contemplated.  
  
[00104] In some embodiments, solvent exchange is included in the
extraction (U.S. Patent Nos. 5,294,443; 5,500,340; 5,580,562;
5,846,742; 5,916,564, the disclosures of which are incorporated
herein by reference in their entireties). In such embodiments, the
extracting step comprises combining the concentrated filtrate with
an excess (v/v) of a polar organic solvent (e.g., ethyl acetate)
relative to original root mass to produce an extract mixture,
which also may be concentrated as described above. The polar
organic solvent (e.g. , ethyl acetate) is different from the
alcohol solvent used to prepare the extract in the extracting
step. This process is repeated until the solvent exchange reduces
the extractant fluid (e.g., alcohol) concentration in the extract
mixture to 15% or less by weight. In some embodiments, the process
is repeated until the extractant fluid concentration in the
extract mixture is 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less
by weight. The concentration of the extractant fluid can be
determined by methods known in the art (e.g., NMR).  
  
[00105] In some embodiments, the extract mixture is filtered to
remove insoluble components, and the filtered extract solution is
processed further by one of the methods described herein.  
  
**V. Methods of processing an alcoholic extract of a TwHF plant
into a freely flowable solid**  
[00106] In another aspect, described herein is a method of
processing an alcoholic extract of a TwHF plant into a freely
flowable solid. In some embodiments, the method comprises
obtaining an alcoholic extract of a TwHF plant, combining the
alcoholic extract with a non- polar organic solvent to produce an
extract/non-polar organic solvent mixture; filtering the
extract/non-polar organic solvent mixture to isolate a solid
precipitate and drying the solid precipitate, thereby processing
the alcoholic extract into the form of a freely flowable solid. In
some embodiments, the alcoholic extract is subjected to solvent
exchange prior to the combining step, wherein the solvent exchange
comprises exchanging the alcohol in the alcoholic extract for a
polar organic solvent such as ethyl acetate. In such embodiments,
the extract/ethyl acetate mixture is combined with the non-polar
organic solvent in the combining step.  
  
[00107] Suitable non-polar organic solvents include any of the
C4-C10 straight- or branched-chain alkanes and cycloalkanes. In
some embodiments, the non-polar organic solvent is a
straight-chain alkane such as pentane, hexane, heptane, octane,
nonane or decane. In some embodiments, the non-polar organic
solvent is heptane. In other embodiments, the non-polar organic
solvent is a branched-chain alkane, such as isopentane, isohexane,
isoheptane, isooctane, isononane or isodecane. In some
embodiments, the non-polar organic solvent is isooctane.  
  
[00108] The combining step comprises contacting, mixing or putting
together the alcoholic extract (or extract/ethyl acetate mixture)
with an excess volume, such as 2- to 20-volumes, of a non-polar
organic solvent relative to the original root mass to produce an
admixture. In some embodiments, the combining step occurs under
vacuum. In some embodiments, the combining step is repeated until
the level of non-polar organic solvent in the admixture is
undetectable. The admixture is filtered to collect solid
precipitate material and subjected to one or more washes with the
non-polar organic solvent. Filtering the admixture can be
performed by conventional methods known in the art and can be
repeated, if desired.  
  
[00109] In an alternative aspect, the method comprises obtaining
an alcoholic extract of a TwHF plant, combining the alcoholic
extract with an excipient under vacuum to produce an
extract/excipient mixture; and drying the concentrated mixture,
thereby producing the extract in the form of a freely flowable
solid. In some embodiments, the alcoholic extract is subjected to
solvent exchange prior to the combining step, wherein the solvent
exchange comprises exchanging the alcohol in the alcoholic extract
for a polar organic solvent such as ethyl acetate. In such
embodiments, the extract/ethyl acetate mixture is combined with
the excipient in the combining step.  
  
[00110] The combining step comprises contacting, mixing and/or
putting together the alcoholic extract (or extract/ethyl acetate
mixture) with an appropriate amount of excipient (compared to the
total solid content in the extract), such as 0.5- to 20-fold
(w/w), and optionally stirring for a time sufficient to mix the
excipient and the extract. Use of an excipient in an amount of
about 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, 14-,
15-, 16-, 17-, 18-, 19-fold excess (w/w) relative to the solid
content of the extract is also contemplated. Suitable excipients
for use in the methods described herein include microcrystalline
cellulose (MCC), maltodextrin, Aerosil(R) (fumed silica), corn
starch, and Neusilin (magnesium aluminometasilicate). In some
embodiments, the excipient is MCC. In some embodiments, the
combining step comprises concentrating the extract/excipient
mixture under full vacuum at a temperature not to exceed 50[deg.]C
(e.g., about 20[deg.]C, 30[deg.]C, 35[deg.]C, 36[deg.]C,
37[deg.]C, 38[deg.], 39[deg.]C, 40[deg.]C, 41[deg.]C, 42[deg.]C,
43[deg.]C, 44[deg.]C, 45[deg.]C, 46[deg.]C, 47[deg.]C, 48[deg.]C
or about 49[deg.]C) until a dry solids content of approximately
80% is achieved in the concentrated excipient mixture.  
  
[00112] Extracts of TwHF contain more than 200 compounds,
including diterpenoids, triterpenoids, sesquiterpenoids,
[beta]-sitosterol, dulcitol and glycosides. Exemplary compounds
include, but are not limited to, triptolide, tripdiolide,
polpunonic acid (wilfortrine) and the methyl ester thereof,
triptophenolide, triptophenolide methyl ether, triptonoterpenol,
wilformine, wilforine, wilforgine, and wilforzine. In some
embodiments, it is desirable to determine the amount of one or
more of these compounds in the freely flowable solid. The
determination of compounds in a sample can be determined by
methods known in the art such as NMR or HPLC...  
  
[00116] The native extract of a TwHF plant is a waxy, amorphous
solid that requires extraordinary means to produce a useable drug
product. Described herein are improved methods of processing the
native extract of a TwHF plant into a freely flowable solid (e.g.,
a flowable powder).  
  
[00117] In one aspect, the method comprises combining the native
extract with a non- polar organic solvent to produce a mixture
thereof; filtering the mixture to collect a solid precipitate and
drying the solid precipitate, thereby producing the native extract
in the form of a freely flowable solid. Suitable non-polar organic
solvents include any of the C4-C10 straight- or branched-chain
alkanes and cycloalkanes. In some embodiments, the non-polar
organic solvent is a straight-chain alkane such as pentane,
hexane, heptane, octane, nonane or decane. In some embodiments,
the non-polar organic solvent is heptane. In other embodiments,
the non-polar organic solvent is a branched-chain alkane, such as
isopentane, isohexane, isoheptane, isooctane, isononane or
isodecane. In some embodiments, the non- polar organic solvent is
isooctane.  
  
[00118] In some embodiments, the non-polar organic solvent/extract
mixture is filtered to collect solid precipitate material.
Filtering the non-polar organic solvent/extract mixture can be
performed by conventional methods known in the art. Once
collected, the solids are subjected to one or more washes with a
non-polar organic solvent.  
  
[00119] In another aspect, the method comprises mixing a native
extract of a TwHF plant with a polar organic solvent (e.g., an
alcohol) to produce an extract/polar organic solvent mixture;
combining the extract/polar organic solvent mixture with an
excipient under vacuum at a temperature of no more than 50[deg.]C
to produce a concentrated mixture; and drying the concentrated
mixture at a temperature suitable to remove remaining polar
solvent from the mixture, thereby producing the native extract in
the form of a freely flowable solid. Suitable polar organic
solvents for use in this processing method include, but are not
limited to, ethanol, ethyl acetate, isopropanol, n-butanol,
n-propanol and methanol. In some embodiments, the polar organic
solvent is ethanol. [00120] In some embodiments, the adding step
comprises incorporating an excess amount of an excipient (w/v),
such as 0.5- to 20-fold, into the polar solvent/extract mixture
and optionally stirring for a time sufficient to mix the excipient
into the polar solvent/extract mixture to produce an excipient
mixture. Mixing an excipient amount of about 1-, 2-, 3-, 4-, 5-,
6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, 14-, 15-, 16-, 17-, 18-,
19-fold excess (w/v) over the polar solvent/extract mixture is
also contemplated. Suitable excipients for use in the methods
described herein include microcrystalline cellulose (MCC),
maltodextrin, Aerosil(R) (fumed silica), corn starch, and Neusilin
(magnesium aluminometasilicate). In some embodiments, the
excipient is MCC.  
  
[00121] In embodiments where an excipient is added to the organic
solvent/extract mixture, no filtration step is performed.  
  
[00122] The washed solids, or excipient mixture, are then dried
for a time sufficient to remove the organic solvent from the
solids, or excipient mixture, respectively. In some embodiments,
the drying step is performed for a time period of about 8-24
hours. Drying the washed solids, or excipient mixture, for about 9
hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours,
16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22
hours, 23 hours, 24 hours or more is specifically contemplated.
Drying the washed solids, or excipient mixture, for less than 8
hours is also contemplated. The washed solids, or excipient
mixture, can be dried in the air or in any drying apparatus known
in the art including, but not limited to, a tray dryer, a vacuum
oven or an oven. In some embodiments, the washed solids, or
excipient mixture, are dried in a drying apparatus at a
temperature of about 20[deg.]C, 25[deg.]C, 30[deg.]C, 35[deg.]C,
40[deg.], 45[deg.]C or about 50[deg.]C.  
  
**VII. Pharmaceutical compositions and routes of administration
of a TwHF extract**  
  
[00128] The amount and administration regimen of the processed
TwHF extract is based on various factors relevant to the purpose
of administration, for example human or animal age, sex, body
weight, hormone levels, or nutritional need of the human or
animal. In some embodiments, the TwHF extract is administered
daily to an animal in an amount from about 0.001 mg/kg body weight
to about 10 g/kg body weight. In some embodiments, the processed
TwHF extract is administered to an animal in an amount of about
0.005 mg/kg body weight per day, or about 0.01, 0.05, 0.1, 0.2,
0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, or
about 10 mg/kg body weight per day...  
  
[00130] Treatment with a processed TwHF extract is continued for
at least about 1 week. Duration of treatment lasting about 2
weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6
months, 7 months, 8 months, 9 months, 10 months, 11 months, 1
year, 5 years or up to lifetime treatment is also contemplated...  
  
**Example 1. Preparation of a freeze-dried debarked root of a
TwHF plant.**  
  
[00133] The improved TwHF extracts according to the disclosure are
more amenable to manipulation as a result of improved flow
properties and exhibit improved safety profiles as a result of
reduced toxin contamination from T. wilfordii bark components. The
reduction in toxin content is achieved by preparing T. wilfordii
roots and root portions in a manner that facilitates quantitative
or near-quantitative bark removal in an efficient manner. More
particularly, the TwHF roots and/or root portions are freeze-dried
in preparation for debarking.  
  
[00134] A total of 308g of fresh TwHF root material (91g medium
roots (3-10mm in length), 15g small (1.00-3.00 mm in length), 29g
root hairs (1.00 or less in length), 30g stumps and 143g large
roots (10.00 mm or larger in length)) were placed in Pyrex trays
and frozen overnight at -20[deg.]C. The freeze-drying (Labconco)
chamber was adjusted to -50[deg.]C and allowed to equalize
overnight. The root material was then placed in the freeze-drying
chamber and the vacuum was set to a pressure of 3-10 millibar. The
chamber temperature was raised to 10[deg.]C for four hours, then
raised to 25[deg.]C for an additional four hours, and then finally
raised to 35[deg.]C for overnight. The resulting freeze-dried root
material was removed from the freeze-drying chamber.  
  
[00135] Freeze-drying the root material caused cracking of the
bark from the root core, which was observed upon visual inspection
of the freeze-dried root material. To remove the bark, the
freeze-dried root material was pressed or rolled with mild
pressure on a flat surface or in a compression device (e.g., a
pasta roller) to remove the bark from the root core. The process
of removing the bark created a fine beige to pink dust/powder,
which was attributed to the bark. Seventeen grams of dried
debarked root material were obtained.  
  
[00136] The mild pressure did not pulverize the TwHF roots and/or
root portions, and these materials were readily separable from any
residual dust or powder, ensuring minimal bark toxins would be
found in any subsequent root extract. It will be apparent to one
of skill in the art that many other mechanical and
electromechanical operations will prove suitable for removing the
bark from the freeze-dried roots and/or root portions, and all
such operations known in the art are contemplated by the
disclosure.  
  
[00137] The foregoing Example demonstrates that any known method
of freezing TwHF root portions known in the art is suitable for
use in the methods described herein. Additionally, the
freeze-drying process may involve any apparatus capable of
controlling the pressure of the atmosphere immediately surrounding
the TwHF root portions. As with most freeze-drying methodologies,
moreover, the length of time that the initially frozen TwHF root
portions are exposed to the freeze-drying process may vary,
provided that sufficient time is allowed to reduce the water
content of the root portions to acceptable levels, e.g., less than
2%.  
  
**Example 2. Preparation of a freely flowable solid from a native
extract of a TwHF plant using a non-polar organic fluid as a
co-processing agent.**  
[00138] TwHF root portions debarked according to the disclosure
provide a desirable substrate for extract preparation because the
efficient and thorough debarking minimizes, or eliminates, bark
toxins that can contaminate TwHF extracts. In addition to
addressing the issue of toxins by providing improved debarking
procedures, the disclosure provides processes for improving the
flow characteristics of extracts prepared from the debarked TwHF
root portions. This Example describes a method of producing a
freely flowable solid from an extract of a TwHF plant using a
non-polar organic fluid (e.g., hexane) as a coprocessing agent.  
  
[00139] Briefly, 10 g of the native extract obtained from debarked
roots from Chinese TwHF plants (i.e., TwHF plant grown in China)
were combined with 100 mL hexane (Fisher Reagent Grade) in a 250
mL beaker. A stainless steel spatula was used to break up the
extract into pieces. The hexane/extract mixture was then sonicated
for 30 minutes at room temperature. The hexane/extract mixture was
then placed in a Buchner funnel, filtered and washed with 100 mL
hexane to produce a filtrate (which was yellow/orange in color)
comprising the hexane wash flow-through and a retentate (which was
brown/red in color) comprising the solids in the hexane/extract
mixture. The hexane/extract mixture was filtered until the
retentate was dry. The retentate was then subjected to repeated
washings with 100 mL hexane until a colorless filtrate was
observed. The retentate was dried overnight in a vacuum oven (100
millibar, 40[deg.]C) to remove any residual hexane from the
retentate. The dried retentate was in the form a freely flowable
solid with a yield of 6.7g.  
  
[00140] To assess the scalability of the method to commercial
quantities, the process was also applied to a larger quantity of
the native extract. Fifty grams of an ethanol extract obtained
from debarked roots of Chinese TwHF plants were combined with 250
mL hexane in a 500 mL beaker. Simple extracts of TwHF, such as the
ethanol extract, are viscous, almost tar-like, amorphous masses
that are difficult to manipulate. A stainless steel spatula was
used to break up the extract into pieces. The hexane/extract
mixture was then stirred for 30 minutes at room temperature. The
hexane/extract mixture was then placed in a Buchner funnel,
filtered and washed with 100 mL hexane to produce a filtrate
(which was  
yellow/orange in color) comprising the hexane wash flow-through
and a retentate (which was brown/red in color) comprising the
solids in the hexane/extract mixture. The hexane/extract mixture
was filtered until the retentate was dry. The retentate was then
subjected to repeated washings with 100 mL hexane until a
colorless filtrate was observed. The retentate was dried overnight
in a vacuum oven (CascadeTek; 100 millibar) at room temperature to
remove any residual hexane from the retentate. The dried retentate
was in the form of a freely flowable solid with a yield of 35.5 g.
The results established that the method would scale to
commercially useful quantities.  
  
[00141] These results showed that a TwHF extract processed by
exposure to a non-polar organic fluid such as hexane, would result
in a TwHF extract that was a freely flowable solid amenable to
manipulations to formulate the extract in forms suitable for
nutritional supplementation or therapeutic treatment, including
but not limited to such forms as capsules, tablets, gels, creams,
and the like. It is expected that any C4-C10 straight-chain or
branched- chain alkane or alkene will be suitable in processing
TwHF extracts to yield freely flowable extract solids.  
  
**Example 3. Preparation of a freely flowable solid from a native
extract of a TwHF plant using another non-polar organic fluid as
a co-processing agent.**  
[00142] Consistent with the expectation, stated in Example 2, that
any C4-C10 straight- or branched-chain alkane or alkene would be
useful in producing a freely flowable solid form of TwHF extract,
this Example describes a method of producing a freely flowable
solid from an extract of a TwHF plant using a non-polar organic
fluid (e.g., heptane) as a co-processing agent.  
  
[00143] Ten grams of a native extract from the root of a Chinese
TwHF plant was combined with 100 mL heptane (Fisher Reagent Grade)
in a 250 mL beaker. A stainless steel spatula was used to break up
the extract into pieces. The heptane/extract mixture was then
stirred for about 20-30 minutes at room temperature until the
extract had dissolved. The heptane/extract mixture was then placed
in a Buchner funnel, filtered and washed with 100 mL heptane to
produce a filtrate (which was yellow/light orange in color)
comprising the heptane wash flow-through and a retentate
comprising the solids in the heptane/extract mixture. The
heptane/extract mixture was filtered until the retentate was dry.
The retentate was then subjected to repeated washings with lOOmL
heptane until a colorless filtrate was observed. The retentate was
dried overnight in a vacuum oven (100 millibar; 50[deg.]C) to
remove any residual heptane from the retentate. The dried
retentate was in the form of a freely flowable solid with a yield
of 6.4g.  
  
[00144] The experiment was then scaled up and repeated. The native
extract (50 g) obtained from debarked roots of Chinese TwHF plants
were combined with 300 mL heptane in a 500 mL beaker. A stainless
steel spatula was used to break-up the extract into pieces. The
heptane/extract mixture was then stirred for about 20-30 minutes
at room temperature until the extract had dissolved. The heptane
extract mixture was then placed in a Biichner funnel, filtered and
washed with 100 mL heptane to produce a filtrate comprising the
heptane wash flow-through (which was yellow/light orange in color)
and a retentate comprising the solids in the heptane/extract
mixture. The heptane/extract mixture was filtered until the
retentate was dry. The retentate was then subjected to repeated
washings with 100 mL heptane until a colorless filtrate was
observed. The retentate was dried overnight in a vacuum oven
(CascadeTek; 100 millibar; 50[deg.]C) to remove any residual
heptane from the retentate. The dried retentate was in the form of
a freely flowable solid with a yield of 30.0 g, establishing that
the method would be suitable for commercially useful quantities.  
  
[00145] The freely flowable character of TwHF extracts processed
with either hexane (Example 2) or heptane (the present Example)
establish that contacting a TwHF extract with a non-polar organic
fluid, such as a C4-C10 straight- or branched-chain alkane will
produce a freely flowable solid form of the extract, amenable to
formulation into nutritional supplements or therapeutics.  
  
**Example 4. Alternative method of producing a freely flowable
solid from an ethanol extract of the roots of a TwHF plant using
heptane as co-processing agent.**  
[00146] This Example describes an alternative method of producing
a freely flowable solid from an ethanol extract of a TwHF plant.
Freeze-dried debarked roots of a TwHF plant were milled and then
combined with 8 volumes of ethanol relative to the volume of the
roots and stirred at reflux (78[deg.]C) for 6 hours. The ethanol
extract was then filtered to produce a first filtrate and moved to
a holding tank. The debarked and milled roots were then combined
with an additional 8 volumes of ethanol in a second ethanol
extraction and stirred at reflux (78[deg.]C) for 6 hours. The
second ethanol extract was filtered to produce a second filtrate.
The first and second filtrates were combined and then concentrated
under vacuum at room temperature to produce a concentrated
filtrate mixture. The resulting concentrated filtrate mixture was
approximately 0.9 volumes relative to the original root mass.  
  
[00147] The concentrated filtrate mixture was then combined with
1.2 volumes ethyl acetate, relative to original root volume, and
concentrated under vacuum with the ethanol removed by
distillation. This process was repeated until the solvent exchange
reduced the ethanol concentration to less than 15% by weight, as
determined by NMR, resulting in an ethyl acetate mixture. The
ethyl acetate mixture was combined with 3.3 volumes of heptane
relative to the original root volume, to produce a heptane
mixture, and the mixture concentrated under vacuum, with the ethyl
acetate removed by distillation. This process was repeated until
the solvent exchange reduced the ethyl acetate concentration to
undetectable levels, as determined by NMR. The heptane mixture was
then filtered and the solids were collected. The solids were
washed with heptane until the flow-through was colorless. The
washed solids were then dried in a tray dryer at about 40[deg.]C
for about 8-12 hours.  
  
[00148] The dried material was a freely flowable solid. This
Example confirms that processing an extract of the TwHF plant with
a straight-chain C4-C10 alkane, i.e., heptane, results in a freely
flowable solid that is suitable for therapeutic or nutritional
formulations. Moreover, the Example establishes that there are
alternative methods for exposing a TwHF extract to a non-polar
organic fluid to produce the extract in the form of a freely
flowable solid.  
 **Example 5. Large-scale preparation of a freely flowable solid
from an ethanol extract from the roots of a TwHF plant using
heptane as co-processing agent.**  
[00149] The process described in Example 4 was repeated multiple
times with debarked root portions from Chinese TwHF plants in
amounts of approximately 100 kg (n=3), 250.4 kg (n=2), 250.2 kg
(n=3) 211.2kg (n=l) and 286.6 kg (n=l) to produce a freely
flowable solid. The starting root material and resulting freely
flowable solid material were analyzed by HPLC to fractionate
components of the extract and to determine the concentration of
triptolide and tripdiolide in the various samples tested. The
results of the experiment are set forth in Table 1...  
  
[00153] Tables 1-3 reveal that the freely flowable solid contains
concentrated triptolide and tripdiolide compared to the fresh root
samples tested. The concentrated levels of triptolide and
tripdiolide present in the freely flowable solid produced by
processing a native extract of TwHF with heptane allows for the
administration of lower dosages of the freely flowable solid to
subjects in need of treatment with triptolide and/or tripdiolide
in comparison to an extract of TwHF processed by conventional
methods.  
  
[00154] In addition, the data in this Example demonstrate that the
celastrol content is low in extracts obtained from root portions
that were freeze-dried prior to bark removal. Thus, the
freeze-drying of TwHF root portions prior to bark removal allows
for the preparation of extracts containing not only concentrated
levels of bioactives (e.g., triptolide and tripdiolode) but also
having a reduction in toxicity (e.g., celastrol content) in
comparison to the toxicity of an extract of TwHF processed from
root portions that were not freeze-dried prior to being debarked
using conventional methods...  
  
[00157] Results showed that microcrystalline cellulose (MCC)
performed better than any other tested excipient in that it
produced a TwHF extract in the form of a non-cakey, flowable
solid. Although other excipients are expected to prove suitable
for use in preparing freely flowable solid forms of TwHF extracts,
further work described herein addressed freely flowable solids
produced using MCC. Based on the flowability of extracts processed
with MCC, the processing of extracts with MCC was scaled up in a
manner analogous to the commercial scale experiments described in
Examples 3 and 4 and the triptolide and tripdiolide concentrations
in the resulting freely flowable solid were analyzed. The results
are set forth in Table 5...  
  
**Example 7. An alternative method of producing a freely flowable
solid from an ethanol extract of a TwHF plant using
microcrystalline cellulose as a co-processing agent.**  
[00159] Described in this Example is an alternative method of
producing a TwHF extract in a freely flowable solid form by
exposing an ethanol extract of a TwHF plant part to an excipient
such as MCC. Freeze-dried debarked root portions of a TwHF plant
were milled and then combined with 8 volumes of ethanol
(approximately 4 L) relative to the mass of the root portions
(approximately 500 g) and stirred at reflux (78[deg.]C) for 6
hours. The ethanol extract was then filtered to produce a first
filtrate and moved to a holding tank. The debarked and milled root
portions were then combined with an additional 8 volumes of
ethanol in a second ethanol extraction and stirred at reflux
(78[deg.]C) for 6 hours. The second ethanol extract was filtered
to produce a second filtrate. The first and second filtrates were
combined and then concentrated under vacuum to produce a
concentrated filtrate. The resulting concentrated filtrate was
approximately 0.9 volumes relative to the original root volume.  
  
[00160] The concentrated filtrate was then combined with 1.2
volumes ethyl acetate, relative to original root mass, and
concentrated under vacuum at 50[deg.]C with the ethanol removed by
distillation. This process was repeated until solvent exchange
reduced the ethanol concentration to 15% or less by weight as
determined by NMR, resulting in an ethyl acetate mixture. The
ethyl acetate mixture was then combined with an appropriate amount
of an excipient (compared to the total solid content in the ethyl
acetate mixture) and mixed thoroughly. The ethyl acetate/excipient
mixture was then concentrated under full vacuum at a temperature
not to exceed 55[deg.]C until a dry solids content of
approximately 80% was achieved in the ethyl acetate/excipient
mixture. The concentrated mixture was then dried in a vacuum dryer
under full vacuum at a temperature not to exceed 55[deg.]C to
remove ethyl acetate from the concentrated mixture. After the
drying process was completed, the dried solid was in the form of a
freely flowable solid.  
  


---

      

**Application of triptolide in
preparation of medicament for treating or preventing human
immunodeficiency viruses (HIV)**  
**CN102755335**

  
Abstract -- The invention discloses an application of triptolide
in preparation of a medicament for treating or preventing human
immunodeficiency viruses (HIV). The triptolide is diterpenoid
naturally existing in roots of tripterygium wilfordii hook, and
can dose-dependently inhibit replication of I type HIV (HIV-1) in
cells in vitro. The half inhibitory concentrations on HIV-1
inhibition in TZM-b1 cells, JurkatT lymphocytes and human
peripheral blood mononuclear cells are respectively 0.32nM, 0.45nM
and 1.1nM. The triptolide has a remarkable inhibiting effect on
the replication of the HIV-1 in the TZM-b1 cells, the JurkatT
lymphocytes and the human peripheral blood mononuclear cells; and
the triptolide is an active ingredient in Chinese medicinal
tripterygium wilfordii hook, so the triptolide is wide in source.
The compound has a broad prospect for developing anti-HIV-1
medicaments.  
  


---

  

**Other Pertinent Patents via the
European Patent Office Advanced Search**

**Construction method of tripterygium wilfordii cell
immobilization****CN102807974****DITERPENOID TRIEPOXIDES THEIR ISOLATION AND USE****GB1431336****Novel anti-leukemic diterpenoid triepoxides****US4005108****PREPARATION OF ANTITUMOR SUBSTANCE****JPS572699****Method for producing tripdiolide, triptolide and celastrol****US4328309****PREPARATION OF ANTITUMOR SUBSTANCE****JPS585196****CONSTITUTION AND PREPARING PROCESS OF 17-HYDROXY
TRIPTERYGIUM-WILFORDII LACTONE ALCOHOL AND SIMILARS****CN1052859****PREPARING PROCESS AND ANTI-CHILD-BEARING FUNCTION OF
TRIPTERYGIUM-WILFORDII CHLOROLACTONE ALCOHOL****CN1052860****PREPARAING TECHNOLOGY OF EXTRACTED SUBSTANCE OF LEI GONG
GAMBOGL AND ITS BETA-RING DEXTRIN ENVELOP MATTER****CN1051859****PROCESS FOR SYNTHESIZING TRIPTERYGIUM WILFORDII LACTONIC
KETONE****CN1062531****Use of Tripterygium Wilfordii Hook F plant extracts and its
components****FR2728466****Medicine containing tripdiolide for preventing and treating
graft acute rejection****CN1179306****Tripterygium wilfordii regenerated plant and its
preparation process****CN1366810****Novel botanical extract of Tripterygium Wilfordii Hook F.****US2004018260****Method for extracting and separating insecticidal active
substance from Tripterygium wilfordii****CN1543804****Preparation method of thunder godvine extract****CN1656899****Suspended cultured thunder godvine cell prepared
insecticide and method thereof****CN1675999****Chinese traditional medicine Tripterygium wilfordii and
improving technique for attenuation and synergy of its extract****CN1634493****METHODS FOR ISOLATION OF TRIPTOLIDE COMPOUNDS FROM
TRIPTERYGIUM WILFORDII****WO2005077008****Method for extracting catechin and epicatechin from
Tripterygium wilfordii plant****CN1884276****Method for inducing, breeding and transplanting triperygium
wilfordii cluster buds****CN1732756****Enteric coated/sustained release formulation of triperygium
wilfordii and preparation process thereof****CN1969928****Method for separating and preparing triptolide diol from
tripterygium wilfordii****CN1800188****Compound miro-emulsified pesticide of triperygium wilfordii
alkaloid****CN1826904****Compound pesticide of triperygium wilfordii alkaloid****CN1826905****Processing method for reducing the poison of triptolide and
the corresponding preparation****CN101062083****Tripterygium glycosides and their preparation triptolide
content determining method****CN1851452****Tripterygium glycosides and their preparation wilforlide A
content determining method****CN1851453****Farm chemical composition, preparing method and use****CN101069508****A botanical pesticide****CN1883277****Method for separating preparing tripterygium wilfordii
monomer from tripterygium wilfordii by countercurrent flow
chromatography****CN1911932****Medicine for treating osteoporosis and its preparation
method****CN1927378****Slow-release preparation containing polyheteroside of
tripterygium wilfordii****CN101002736****Dry coating sustained-release tablet for treating arthritis
and preparation process thereof****CN1969929****Foot nourishing and protecting mist made of pure
traditional Chinese medicinal and preparation method thereof****CN101011546****Chinese medicinal formulation for treating rheumatic and
rheumatoid disease****CN1966018****Nano-emulsion drug of triperygium wilfordii polycoride and
preparation method thereof****CN1961866****Biological pesticide for pollution-free vegetables and its
manufacturing method****CN101194633****Chinese traditional medicine compound took orally for
treating ankylosing spondylitis****CN101040927****Chinese traditional medicine compound took orally for
treating ankylosing spondylitis****CN101040908****Fuming and steaming medicine for treating arthropathy****CN101040916****Decoction for treating arthritis****CN101062198****Environment friendly pesticides for paddy field and
preparation thereof****CN101317583****Environment friendly pesticides for accelerating plants
growth and preparation thereof****CN101317584****Broad spectrum environment friendly pesticide and
preparation thereof****CN101317585****Environment friendly pesticide for vegetables and
preparation thereof****CN101317586****Optimizing method for attenuation processing of
Tripterygium wilfordii and related formulation****CN101322735****Biology plant pesticides and preparation technique thereof****CN101361492****Four kinds of tripterygium wilfordii derivative and
preparing method of pharmaceutics thereof****CN101235041****Method for inducing adventitious root by thunder god vine
suspending cell****CN101248757****Tripterygium wilfordii total terpene sustained-release
dropping pill and preparation method thereof****CN101269108****Tripterygium wilfordii compound pesticides for high
effectively preventing and curing tea geometrid****CN101288413**  
**Method for extracting triptolide from Tripterygium wilfordii** **CN101434638**  
**Method for establishing Tripterygium wilfordii fingerprint
chromatography and standard fingerprint chromatography thereof** **CN101642481** **Method for cultivating and managing tripterygium wilfordii** **CN101773035**  
**Tripterygium wilfordii hook extract cataplasm and preparation
method thereof** **CN102008536** **Method for inducing production of tripterygium wilfordii
hairy root by agrobacterium rhizogenes** **CN102321664** **METHODS OF PROCESSING EXTRACTS OF A T. WILFORDII HOOK F.
PLANT** **WO2012118942**  


---

  
[**http://eol.org/pages/2888865/overview**](http://eol.org/pages/2888865/overview)

**Tripterygium wilfordii J. D. Hooker**

  

![](eolorg.jpg)

  


---

  
[**http://davesgarden.com**](http://davesgarden.com)  
  
  ![](thundergodvine1.jpg)  
  
![](tgv2.jpg)  
  


---

  
[**http://www.pfaf.org/user/Plant.aspx?LatinName=Tripterygium+wilfordii**](http://www.pfaf.org/user/Plant.aspx?LatinName=Tripterygium+wilfordii)

**Tripterygium wilfordii - Hook.f.**

  
Common Name       
Family     Celastraceae  
Synonyms     T. forrestii. T. hypoglaucum.  
Known Hazards     All parts of the plant are highly
toxic[147, 218].  
Habitats     Field and ditch edges and on the banks
of streams[147].  
Range     E. Asia - S. China to Burma.  
Edibility Rating        
Medicinal Rating        
Care       
Half Hardy     Moist Soil    
Semi-shade     Full sun  
  
**Summary**  
  
**Physical Characteristics**   
Tripterygium wilfordii is a deciduous Climber growing to 12 m
(39ft 4in). It is hardy to zone 9. It is in flower in September.
The flowers are hermaphrodite (have both male and female organs)  
  
Suitable for: light (sandy), medium (loamy) and heavy (clay)
soils. Suitable pH: acid, neutral and basic (alkaline) soils and
can grow in very alkaline soils.  
  
It can grow in semi-shade (light woodland) or no shade. It prefers
moist soil.  
  
**Other Names:**  
Huang-T'eng Ken, Lei Gong Teng, Lei-Kung T'eng, Taso-Ho-Hua,
Threewingnut, Tonnerre de la Vigne de Dieu, Tripterigium
Wilfordii, Tripterygium wilfordii, Vigne du Tonnerre Divin, Yellow
Vine.  
  


---